OA17560A - Sequestrants of advanced glycation end product (AGE) precursors. - Google Patents
Sequestrants of advanced glycation end product (AGE) precursors. Download PDFInfo
- Publication number
- OA17560A OA17560A OA1201500377 OA17560A OA 17560 A OA17560 A OA 17560A OA 1201500377 OA1201500377 OA 1201500377 OA 17560 A OA17560 A OA 17560A
- Authority
- OA
- OAPI
- Prior art keywords
- cio
- alkyl
- pharmaceutical composition
- composition according
- polymer
- Prior art date
Links
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 title claims abstract description 88
- 102000014961 Protein Precursors Human genes 0.000 title claims abstract description 85
- 108010078762 Protein Precursors Proteins 0.000 title claims abstract description 85
- 239000003352 sequestering agent Substances 0.000 title abstract description 5
- 239000007795 chemical reaction product Substances 0.000 title description 3
- 230000036252 glycation Effects 0.000 title description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 96
- 125000004989 dicarbonyl group Chemical group 0.000 claims abstract description 29
- 235000005911 diet Nutrition 0.000 claims abstract description 22
- 241000124008 Mammalia Species 0.000 claims abstract description 19
- 230000000378 dietary Effects 0.000 claims abstract description 14
- 125000000217 alkyl group Chemical group 0.000 claims description 186
- 229920000642 polymer Polymers 0.000 claims description 151
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 134
- 125000003118 aryl group Chemical group 0.000 claims description 85
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 75
- 125000001072 heteroaryl group Chemical group 0.000 claims description 75
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 74
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 74
- 150000003973 alkyl amines Chemical class 0.000 claims description 70
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 69
- BRLQWZUYTZBJKN-UHFFFAOYSA-N epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 claims description 57
- 150000001408 amides Chemical class 0.000 claims description 53
- 150000001875 compounds Chemical class 0.000 claims description 50
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 43
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 26
- 150000001450 anions Chemical class 0.000 claims description 15
- 229920001577 copolymer Polymers 0.000 claims description 12
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 7
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 7
- 229920001223 polyethylene glycol Polymers 0.000 claims description 6
- PJJJBBJSCAKJQF-UHFFFAOYSA-N Guanidinium chloride Chemical group [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 claims description 5
- 239000002202 Polyethylene glycol Substances 0.000 claims description 5
- 125000003827 glycol group Chemical group 0.000 claims description 5
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 claims description 5
- QRJZGVVKGFIGLI-UHFFFAOYSA-N 2-phenylguanidine Chemical group NC(=N)NC1=CC=CC=C1 QRJZGVVKGFIGLI-UHFFFAOYSA-N 0.000 claims description 4
- 150000003841 chloride salts Chemical group 0.000 claims 1
- 150000001412 amines Chemical class 0.000 abstract description 7
- 210000001035 Gastrointestinal Tract Anatomy 0.000 abstract description 6
- 206010003210 Arteriosclerosis Diseases 0.000 abstract description 5
- 208000007342 Diabetic Nephropathy Diseases 0.000 abstract description 5
- 206010061835 Diabetic nephropathy Diseases 0.000 abstract description 5
- 201000001320 atherosclerosis Diseases 0.000 abstract description 5
- 201000000522 chronic kidney disease Diseases 0.000 abstract description 5
- 206010001897 Alzheimer's disease Diseases 0.000 abstract description 4
- 208000002177 Cataract Diseases 0.000 abstract description 4
- 208000006011 Stroke Diseases 0.000 abstract description 4
- 239000008177 pharmaceutical agent Substances 0.000 abstract description 2
- -1 methylenedioxyl Chemical group 0.000 description 108
- 239000011541 reaction mixture Substances 0.000 description 104
- 239000000243 solution Substances 0.000 description 92
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 73
- AIJULSRZWUXGPQ-UHFFFAOYSA-N pyruvic aldehyde Chemical compound CC(=O)C=O AIJULSRZWUXGPQ-UHFFFAOYSA-N 0.000 description 60
- 230000015572 biosynthetic process Effects 0.000 description 59
- 239000000499 gel Substances 0.000 description 52
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 51
- 238000003786 synthesis reaction Methods 0.000 description 49
- 230000002194 synthesizing Effects 0.000 description 49
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 42
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 39
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 36
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 32
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 32
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- 229910052757 nitrogen Inorganic materials 0.000 description 30
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 27
- 239000002904 solvent Substances 0.000 description 24
- 238000003756 stirring Methods 0.000 description 23
- 239000000047 product Substances 0.000 description 22
- 239000007787 solid Substances 0.000 description 21
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 18
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 18
- 239000011521 glass Substances 0.000 description 17
- 239000012528 membrane Substances 0.000 description 17
- 238000001816 cooling Methods 0.000 description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 16
- 125000003277 amino group Chemical group 0.000 description 15
- 238000001914 filtration Methods 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 14
- 238000000502 dialysis Methods 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- 239000000725 suspension Substances 0.000 description 13
- QYPPJABKJHAVHS-UHFFFAOYSA-N agmatine Chemical compound NCCCCNC(N)=N QYPPJABKJHAVHS-UHFFFAOYSA-N 0.000 description 12
- 125000004429 atoms Chemical group 0.000 description 12
- 229910052799 carbon Inorganic materials 0.000 description 11
- 239000000706 filtrate Substances 0.000 description 11
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 10
- 238000005755 formation reaction Methods 0.000 description 10
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 description 10
- 239000012074 organic phase Substances 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 10
- PADGNZFOVSZIKZ-UHFFFAOYSA-N 2-(chloromethyl)oxirane;hydrogen carbonate;prop-2-enylazanium Chemical compound NCC=C.OC(O)=O.ClCC1CO1 PADGNZFOVSZIKZ-UHFFFAOYSA-N 0.000 description 9
- 125000004432 carbon atoms Chemical group C* 0.000 description 9
- MYRTYDVEIRVNKP-UHFFFAOYSA-N divinylbenzene Substances C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 9
- 239000008079 hexane Substances 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 9
- 229960005441 sevelamer carbonate Drugs 0.000 description 9
- 239000002002 slurry Substances 0.000 description 9
- ITTDFJBEARSVPJ-UHFFFAOYSA-N 4-ethenylbenzene-1,2-diamine Chemical compound NC1=CC=C(C=C)C=C1N ITTDFJBEARSVPJ-UHFFFAOYSA-N 0.000 description 8
- OZAIFHULBGXAKX-VAWYXSNFSA-N Azobisisobutyronitrile Chemical compound N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 8
- 125000001931 aliphatic group Chemical group 0.000 description 8
- 239000008367 deionised water Substances 0.000 description 8
- 230000037213 diet Effects 0.000 description 8
- 239000000178 monomer Substances 0.000 description 8
- SJRJJKPEHAURKC-UHFFFAOYSA-N n-methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- PIYJQTKZHLLZQE-UHFFFAOYSA-N 2-methyl-N-[2-(2-methylprop-2-enoylamino)ethyl]prop-2-enamide Chemical compound CC(=C)C(=O)NCCNC(=O)C(C)=C PIYJQTKZHLLZQE-UHFFFAOYSA-N 0.000 description 7
- 239000005977 Ethylene Substances 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 238000007792 addition Methods 0.000 description 7
- 239000008346 aqueous phase Substances 0.000 description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 7
- 125000000524 functional group Chemical group 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
- IMSODMZESSGVBE-UHFFFAOYSA-N 2-oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 6
- 239000004475 Arginine Substances 0.000 description 6
- FQPSGWSUVKBHSU-UHFFFAOYSA-N Methacrylamide Chemical compound CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 238000004132 cross linking Methods 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 239000007863 gel particle Substances 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
- UDZLUXXCXDIIOK-UHFFFAOYSA-N 2,3-bis[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)NCC(C(O)=O)NC(=O)OC(C)(C)C UDZLUXXCXDIIOK-UHFFFAOYSA-N 0.000 description 5
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Natural products NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 5
- 229960000643 Adenine Drugs 0.000 description 5
- 210000002381 Plasma Anatomy 0.000 description 5
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229940079593 drugs Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 238000003818 flash chromatography Methods 0.000 description 5
- 239000012456 homogeneous solution Substances 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 229940086542 triethylamine Drugs 0.000 description 5
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N Glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 4
- 229940015043 Glyoxal Drugs 0.000 description 4
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M Lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N MeOtBu Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- 206010038444 Renal failure chronic Diseases 0.000 description 4
- 241000283984 Rodentia Species 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 150000002430 hydrocarbons Chemical class 0.000 description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Inorganic materials [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 4
- 150000003141 primary amines Chemical class 0.000 description 4
- 150000003335 secondary amines Chemical class 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- 239000011593 sulfur Substances 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 150000003512 tertiary amines Chemical class 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 3
- BYNQILVEFANFGH-UHFFFAOYSA-N 4-ethenyl-2-nitroaniline Chemical compound NC1=CC=C(C=C)C=C1[N+]([O-])=O BYNQILVEFANFGH-UHFFFAOYSA-N 0.000 description 3
- DYHSDKLCOJIUFX-UHFFFAOYSA-N Di-tert-butyl dicarbonate Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical group N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 230000005587 bubbling Effects 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000011010 flushing procedure Methods 0.000 description 3
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 150000002829 nitrogen Chemical group 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- OQVOZFPJUCUPLW-LURJTMIESA-N (2S)-6-amino-2-(carboxymethylamino)hexanoic acid Chemical compound NCCCC[C@@H](C(O)=O)NCC(O)=O OQVOZFPJUCUPLW-LURJTMIESA-N 0.000 description 2
- AICIYIDUYNFPRY-UHFFFAOYSA-N 1,3-dihydro-2H-imidazol-2-one Chemical compound O=C1NC=CN1 AICIYIDUYNFPRY-UHFFFAOYSA-N 0.000 description 2
- WEERVPDNCOGWJF-UHFFFAOYSA-N 1,4-bis(ethenyl)benzene Chemical compound C=CC1=CC=C(C=C)C=C1 WEERVPDNCOGWJF-UHFFFAOYSA-N 0.000 description 2
- 125000006325 2-propenyl amino group Chemical group [H]C([H])=C([H])C([H])([H])N([H])* 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-M 3-carboxy-2-(carboxymethyl)-2-hydroxypropanoate Chemical compound OC(=O)CC(O)(C(O)=O)CC([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-M 0.000 description 2
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 2
- 102100001249 ALB Human genes 0.000 description 2
- 101710027066 ALB Proteins 0.000 description 2
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 2
- 229940072107 Ascorbate Drugs 0.000 description 2
- 210000004369 Blood Anatomy 0.000 description 2
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N DL-alanine Chemical compound CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- RFDAIACWWDREDC-FRVQLJSFSA-N Glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 2
- 210000003734 Kidney Anatomy 0.000 description 2
- TYQCGQRIZGCHNB-JLAZNSOCSA-N L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 2
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 2
- ZQXSMRAEXCEDJD-UHFFFAOYSA-N N-ethenylformamide Chemical compound C=CNC=O ZQXSMRAEXCEDJD-UHFFFAOYSA-N 0.000 description 2
- GEYOCULIXLDCMW-UHFFFAOYSA-N O-Phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-J Pyrophosphate Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 2
- 239000002262 Schiff base Substances 0.000 description 2
- 150000004753 Schiff bases Chemical class 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N Sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- 210000002784 Stomach Anatomy 0.000 description 2
- WBWWGRHZICKQGZ-HZAMXZRMSA-N Taurocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 WBWWGRHZICKQGZ-HZAMXZRMSA-N 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M Tetra-n-butylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N Triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- WFDIJRYMOXRFFG-UHFFFAOYSA-N acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 2
- 229940050528 albumin Drugs 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 239000012062 aqueous buffer Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 150000001728 carbonyl compounds Chemical class 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229940099352 cholate Drugs 0.000 description 2
- BHQCQFFYRZLCQQ-OELDTZBJSA-M cholate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-M 0.000 description 2
- 238000010835 comparative analysis Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000000875 corresponding Effects 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 239000001177 diphosphate Substances 0.000 description 2
- 235000011180 diphosphates Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- UYMKPFRHYYNDTL-UHFFFAOYSA-N ethenamine Chemical compound NC=C UYMKPFRHYYNDTL-UHFFFAOYSA-N 0.000 description 2
- 230000002550 fecal Effects 0.000 description 2
- DSLZVSRJTYRBFB-DUHBMQHGSA-L galactarate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C([O-])=O DSLZVSRJTYRBFB-DUHBMQHGSA-L 0.000 description 2
- 238000004817 gas chromatography Methods 0.000 description 2
- 125000005842 heteroatoms Chemical group 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 229940049920 malate Drugs 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-L maleate(2-) Chemical compound [O-]C(=O)\C=C/C([O-])=O VZCYOOQTPOCHFL-UPHRSURJSA-L 0.000 description 2
- 230000002503 metabolic Effects 0.000 description 2
- 230000003278 mimic Effects 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-L oxalate Chemical compound [O-]C(=O)C([O-])=O MUBZPKHOEPUJKR-UHFFFAOYSA-L 0.000 description 2
- 229940039748 oxalate Drugs 0.000 description 2
- 125000004430 oxygen atoms Chemical group O* 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutic aid Substances 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920000083 poly(allylamine) Polymers 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000003389 potentiating Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 125000003003 spiro group Chemical group 0.000 description 2
- 229940086735 succinate Drugs 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 2
- 230000002588 toxic Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-M valerate Chemical compound CCCCC([O-])=O NQPDZGIKBAWPEJ-UHFFFAOYSA-M 0.000 description 2
- 229940070710 valerate Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
- 125000004529 1,2,3-triazinyl group Chemical group N1=NN=C(C=C1)* 0.000 description 1
- 125000004530 1,2,4-triazinyl group Chemical group N1=NC(=NC=C1)* 0.000 description 1
- 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 1
- XFNJVJPLKCPIBV-UHFFFAOYSA-N 1,3-Diaminopropane Chemical compound NCCCN XFNJVJPLKCPIBV-UHFFFAOYSA-N 0.000 description 1
- LLRDKNVOXVJWPB-UHFFFAOYSA-N 1,3-diacetylimidazol-2-one Chemical compound CC(=O)N1C=CN(C(C)=O)C1=O LLRDKNVOXVJWPB-UHFFFAOYSA-N 0.000 description 1
- CAAMSDWKXXPUJR-UHFFFAOYSA-N 1,5-dihydro-4H-imidazol-4-one Chemical compound O=C1CNC=N1 CAAMSDWKXXPUJR-UHFFFAOYSA-N 0.000 description 1
- HJKLEAOXCZIMPI-UHFFFAOYSA-N 2,2-diethoxyethanamine Chemical compound CCOC(CN)OCC HJKLEAOXCZIMPI-UHFFFAOYSA-N 0.000 description 1
- SKWCZPYWFRTSDD-UHFFFAOYSA-N 2,3-bis(azaniumyl)propanoate;chloride Chemical compound Cl.NCC(N)C(O)=O SKWCZPYWFRTSDD-UHFFFAOYSA-N 0.000 description 1
- VMAWODUEPLAHOE-UHFFFAOYSA-N 2,4,6,8-tetrakis(ethenyl)-2,4,6,8-tetramethyl-1,3,5,7,2,4,6,8-tetraoxatetrasilocane Chemical compound C=C[Si]1(C)O[Si](C)(C=C)O[Si](C)(C=C)O[Si](C)(C=C)O1 VMAWODUEPLAHOE-UHFFFAOYSA-N 0.000 description 1
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholino)ethanesulfonic acid Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 1
- WJAXXWSZNSFVNG-UHFFFAOYSA-N 2-bromoethanamine;hydron;bromide Chemical compound [Br-].[NH3+]CCBr WJAXXWSZNSFVNG-UHFFFAOYSA-N 0.000 description 1
- CFMZSMGAMPBRBE-UHFFFAOYSA-N 2-hydroxyisoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(O)C(=O)C2=C1 CFMZSMGAMPBRBE-UHFFFAOYSA-N 0.000 description 1
- VSKJLJHPAFKHBX-UHFFFAOYSA-N 2-methylbuta-1,3-diene;styrene Chemical compound CC(=C)C=C.C=CC1=CC=CC=C1.C=CC1=CC=CC=C1 VSKJLJHPAFKHBX-UHFFFAOYSA-N 0.000 description 1
- WCCVMVPVUAVUFI-UHFFFAOYSA-N 2-methylprop-2-enamide;hydrochloride Chemical compound Cl.CC(=C)C(N)=O WCCVMVPVUAVUFI-UHFFFAOYSA-N 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- YZYQQJHFYIVWPS-UHFFFAOYSA-N 3,4,5,6-tetradehydrothiopyran Chemical group [CH]1SC#CC#C1 YZYQQJHFYIVWPS-UHFFFAOYSA-N 0.000 description 1
- ZGCHLOWZNKRZSN-NTSWFWBYSA-N 3-deoxyglucosone Chemical compound OC[C@@H](O)[C@@H](O)CC(=O)C=O ZGCHLOWZNKRZSN-NTSWFWBYSA-N 0.000 description 1
- 125000004364 3-pyrrolinyl group Chemical group [H]C1=C([H])C([H])([H])N(*)C1([H])[H] 0.000 description 1
- PTAYFGHRDOMJGC-UHFFFAOYSA-N 4-aminobutyl(diaminomethylidene)azanium;hydrogen sulfate Chemical compound OS(O)(=O)=O.NCCCCN=C(N)N PTAYFGHRDOMJGC-UHFFFAOYSA-N 0.000 description 1
- ZCWBZRBJSPWUPG-UHFFFAOYSA-N 4-bromo-2-nitroaniline Chemical compound NC1=CC=C(Br)C=C1[N+]([O-])=O ZCWBZRBJSPWUPG-UHFFFAOYSA-N 0.000 description 1
- JDCCCHBBXRQRGU-UHFFFAOYSA-N 5-phenylpenta-2,4-dienenitrile Chemical compound N#CC=CC=CC1=CC=CC=C1 JDCCCHBBXRQRGU-UHFFFAOYSA-N 0.000 description 1
- 238000003691 Amadori rearrangement reaction Methods 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- JXUQCKZQHUUMSM-UHFFFAOYSA-N Cl.NC(=O)C(C)=CCCN Chemical compound Cl.NC(=O)C(C)=CCCN JXUQCKZQHUUMSM-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 210000003608 Feces Anatomy 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229940001447 Lactate Drugs 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- 208000008466 Metabolic Disease Diseases 0.000 description 1
- VHRYZQNGTZXDNX-UHFFFAOYSA-N Methacryloyl chloride Chemical compound CC(=C)C(Cl)=O VHRYZQNGTZXDNX-UHFFFAOYSA-N 0.000 description 1
- ADJJYEZPSBDGGL-UHFFFAOYSA-N N'-[3-[(2-methoxyphenyl)methyl-methylamino]propyl]-N'-methylpropane-1,3-diamine Chemical compound COC1=CC=CC=C1CN(C)CCCN(C)CCCN ADJJYEZPSBDGGL-UHFFFAOYSA-N 0.000 description 1
- RFZRLVGQBIINKQ-UHFFFAOYSA-N N-(2-aminoethyl)-2-methylprop-2-enamide Chemical compound CC(=C)C(=O)NCCN RFZRLVGQBIINKQ-UHFFFAOYSA-N 0.000 description 1
- XHIRWEVPYCTARV-UHFFFAOYSA-N N-(3-aminopropyl)-2-methylprop-2-enamide;hydrochloride Chemical compound Cl.CC(=C)C(=O)NCCCN XHIRWEVPYCTARV-UHFFFAOYSA-N 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-hydroxy-Succinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- UFGPIZWKXREWTJ-UHFFFAOYSA-N NC(C(=O)N)(CN)NCCNC(C(=C)C)=O Chemical compound NC(C(=O)N)(CN)NCCNC(C(=C)C)=O UFGPIZWKXREWTJ-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene (PE) Substances 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M Potassium bicarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- GKKCIDNWFBPDBW-UHFFFAOYSA-M Potassium cyanate Chemical compound [K]OC#N GKKCIDNWFBPDBW-UHFFFAOYSA-M 0.000 description 1
- 229940048181 SODIUM SULFIDE NONAHYDRATE Drugs 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 229910052789 astatine Inorganic materials 0.000 description 1
- RYXHOMYVWAEKHL-UHFFFAOYSA-N astatine(.) Chemical compound [At] RYXHOMYVWAEKHL-UHFFFAOYSA-N 0.000 description 1
- 244000269888 azena Species 0.000 description 1
- 238000010533 azeotropic distillation Methods 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004622 benzoxazinyl group Chemical group O1NC(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 230000000271 cardiovascular Effects 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000001684 chronic Effects 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 150000001924 cycloalkanes Chemical class 0.000 description 1
- VOLSCWDWGMWXGO-UHFFFAOYSA-N cyclobuten-1-yl acetate Chemical compound CC(=O)OC1=CCC1 VOLSCWDWGMWXGO-UHFFFAOYSA-N 0.000 description 1
- QSJXEFYPDANLFS-UHFFFAOYSA-N diacetyl Chemical compound CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- CNXMDTWQWLGCPE-UHFFFAOYSA-N ditert-butyl-(2-phenylphenyl)phosphane Chemical compound CC(C)(C)P(C(C)(C)C)C1=CC=CC=C1C1=CC=CC=C1 CNXMDTWQWLGCPE-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical group NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 102000035365 modified proteins Human genes 0.000 description 1
- 108091005569 modified proteins Proteins 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 239000001184 potassium carbonate Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (NE)-N-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- ITLXNJZJMGQYRT-UHFFFAOYSA-N pyrazol-3-ylidenemethanediamine;hydrochloride Chemical compound Cl.NC(N)=C1C=CN=N1 ITLXNJZJMGQYRT-UHFFFAOYSA-N 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000001187 sodium carbonate Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- ZGHLCBJZQLNUAZ-UHFFFAOYSA-N sodium sulfide nonahydrate Chemical compound O.O.O.O.O.O.O.O.O.[Na+].[Na+].[S-2] ZGHLCBJZQLNUAZ-UHFFFAOYSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229920000638 styrene acrylonitrile Polymers 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- AOCSUUGBCMTKJH-UHFFFAOYSA-N tert-butyl N-(2-aminoethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCN AOCSUUGBCMTKJH-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 125000005306 thianaphthenyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
Abstract
Sequestrants of AGE precursors comprise amines separated by 2, 3 or 4 carbons. Sequestrants of AGE precursors can be used as pharmaceutical agents and in pharmaceutical compositions. The sequestrants of AGE precursors are particularly useful binding AGE precursors and dietary dicarbonyls in mammals in the gastrointestinal tract for the treatment of ailments such as diabetic nephropathy, chronic renal disease, atherosclerosis, stroke, cataracts, and Alzheimer's disease.
Description
Title of the Invention
SEQUESTRANTS OF ADVANCED GLYCATION END PRODUCT (AGE) PRECURSORS
Cross-Reference to Related Applications
Not applicable
Statement Regarding Federally Sponsored Research
Not applicable
The Names of the Parties to a Joint Research Agreement
Not applicable
Incorporation-by-Reference of Material Submitted on Compact Disc
Not applicable
BACKGROUND OF THE INVENTION
Field of the Invention
This invention relates to séquestrants of advanced glycation end product (AGE) precursors. The séquestrants of AGE precursors bind dietary dicarbonyls, a key precursor in AGE formation. This invention further relates to the use of séquestrants of AGE precursors as pharmaceutical agents and in pharmaceutical compositions and to the use of séquestrants of AGE precursors to bind AGE precursors and dietary dicarbonyls.
Définitions
As used herein, the term “amino” means a functional group having a nitrogen atom and 1 to 2 hydrogen atoms. “Amino” generally may be used herein to describe a primary, secondary, or tertiary amine, and those of skill in the art will readily be able to ascertain the identification of which in view of the context in which this term is used in the présent disclosure. The term “amine” or “amine group” or “ammonia group” means a functional group containing a nitrogen atom derived from ammonia (NH3). The amine groups are preferably primary amines, meaning the nitrogen is bonded to two hydrogen atoms and one substituent group comprising a substituted or unsubstituted alkyl or aryl group or an aliphatic or aromatic group. The amine groups may be secondary amines meaning, the nitrogen is bonded to one hydrogen atom and two substituent groups comprising a substituted or unsubstituted alkyl or aryl groups or an aliphatic or aromatic group, as defined below. The amine groups may be tertiary amines meaning the nitrogen is bonded to three substituent groups comprising a substituted or unsubstituted alkyl or aryl groups or an aliphatic or aromatic group. The amine groups may also be quatemary amines meaning the designated amine group is bonded to a fourth group, resulting in a positively charged ammonium group.
It is understood that any or ail of the amines in the présent invention may be in the free amine form (that is, as -NH2 for a primary amine) or in a protonated form with a pharmaceutically acceptable anion (that is, as -NH3+ Y for a primary amine, where Y’ is the pharmaceutically acceptable anion).
As used herein, the term “amide group” means a functional group comprising a carbonyl group linked to a nitrogen. “Carbonyl” or a “carbonyl group” means a functional group comprising a carbon atom double bonded to an oxygen atom, represented by (C=O).
The term “alkane” means a saturated hydrocarbon, bonded by single bonds. Alkanes can be linear or branched. “Cycloalkanes” are saturated hydrocarbons rings bonded by single bonds.
As used herein, the term “(Ci-Cio)alkyl” means a saturated straight chained or branched or cyclic hydrocarbon consisting essentially of 1 to 10 carbon atoms and a corresponding number of hydrogen atoms. Typically straight chained or branched groups hâve from one to ten carbons, or more typically one to fîve carbons. Exemplary (Ci-Cio)alkyl groups include methyl (represented by -CH3), ethyl (represented by -CH2-CH3), n-propyl, isopropyl, n-butyl, isobutyl, etc. Other (Ci-C-io)alkyl groups will be readily apparent to those of skill in the art given the benefit of the présent disclosure.
As used herein, the term “(C2-C9)heteroalkyl” means a saturated straight chained or branched or cyclic hydrocarbon consisting essentially of 2 to 10 atoms, wherein 2 to 9 of the atoms are carbon and the remaining atom(s) is selected from the group consisting of nitrogen, sulfur, and oxygen. Exemplary (C2-C9)heteroalkyl groups will be readily apparent to those of skill in the art given the benefit of the présent disclosure.
As used herein, the term “(C3-Cio)cycloalkyl” means a nonaromatic saturated hydrocarbon group, forming at least one ring consisting essential of 3 to 10 carbon atoms and a corresponding number of hydrogen atoms. (C3-Cio)cycloalkyl groups can be monocyclic or multicyclic. Individual rings of multicyclic cycloalkyl groups can hâve different connectivities, for example, fiised, bridged, spiro, etc., in addition to covalent bond substitution. Exemplary (C3-Cio)cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, norbomanyl, bicyclo-octanyl, octahydro-pentalenyl, spiro-decanyl, cyclopropyl substituted with cyclobutyl, cyclobutyl substituted with cyclopentyl, cyclohexyl substituted with cyclopropyl, etc. Other (C3-Cio)cycloalkyl groups will be readily apparent to those of skill in the art given the benefit of the présent disclosure.
As used herein, the term “(C2-C9)heterocycloalkyl” means a nonaromatic group having 3 to 10 atoms that form at least one ring, wherein 2 to 9 of the ring atoms are carbon and the remaining ring atom(s) is selected from the group consisting of nitrogen, sulfur, and oxygen. (C2-C9)heterocycloalkyl groups can be monocyclic or multicyclic. Individual rings of such multicyclic heterocycloalkyl groups can hâve different connectivities, for example, fiised, bridged, spiro, etc., in addition to covalent bond substitution. Exemplary (C2-C9)heterocycloalkyl groups include pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydropyranyl, pyranyl, thiopyranyl, aziridinyl, azetidinyl, oxiranyl, methylenedioxyl, chromenyl, barbituryl, isoxazolidinyl,
1.3- oxazolidin-3-yl, isothiazolidinyl, l,3-thiazolidin-3-yl, l,2-pyrazolidin-2-yl,
1.3- pyrazolidin-l-yl, piperidinyl, thiomorpholinyl, l,2-tetrahydrothiazin-2-yl,
1.3- tetrahydrothiazin-3-yl, tetrahydrothiadiazinyl, morpholinyl, l,2-tetrahydrodiazin-2-yl,
1.3- tetrahydrodiazin-l-yl, tetrahydroazepinyl, piperazinyl, piperizin-2-onyl, piperizin-3-onyl, chromanyl, 2-pyrrolinyl, 3-pyrrolinyl, imidazolidinyl, 2-imidazolidinyl,
1.4- dioxanyl, 8-azabicyclo[3.2.1 ]octanyl, 3-azabicyclo[3.2.1 ]octanyl,
3,8-diazabicyclo[3.2.1]octanyl, 2,5-diazabicyclo[2.2.1]heptanyl,
2.5- diazabicyclo [2.2.2]octanyl, octahydro-2H-pyrido[ 1,2-a]pyrazinyl,
3-azabicyclo[4.1.0]heptanyl, 3-azabicyclo[3.1.0]hexanyl, 2-azaspiro[4.4]nonanyl, 7-oxa-l-aza-spiro[4.4]nonanyl, 7-azabicyclo[2.2.2]heptanyl, octahydro-lH-indolyl, etc. The (C2-C9)heterocycloalkyl group is typically attached to the main structure via a carbon atom or a nitrogen atom. Other (C2-C9)heterocycloalkyl groups will be readily apparent to those of skill in the art given the benefit of the présent disclosure.
The term “aliphatic group” or “aliphatic” means a non-aromatic group consisting of carbon and hydrogen, and may optionally include one or more double and/or triple bonds. In other words, an aliphatic group is any group consisting of carbon and hydrogen which contains no aromatic functionality. An aliphatic group may be straight chained, branched or cyclic and typically contains between about one and about 24 carbon atoms.
The term “aryl group” may be used interchangeably with “aryl,” “aryl ring,” “aromatic,” “aromatic group,” and “aromatic ring.” Aryl groups include carbocyclic aromatic groups, typically with six to fourteen ring carbon atoms. Aryl groups also include heteroaryl groups, which typically hâve five to fourteen ring atoms with one or more heteroatoms selected from nitrogen, oxygen and sulfur.
As used herein, the term “(Cô-Ci4)aryl” means an aromatic functional group having 6 to 14 carbon atoms that form at least one ring.
As used herein, the term “(C2-C9)heteroaryl” means an aromatic functional group having 5 to 10 atoms that form at least one ring, wherein 2 to 9 of the ring atoms are carbon and the remaining ring atom(s) is selected from the group consisting of nitrogen, sulfur, and oxygen. (C2-C9)heteroaryl groups can be monocyclic or multicyclic. Individual rings of such multicyclic heteroaryl groups can hâve different connectivities, for example, fused, etc., in addition to covalent bond substitution. Exemplary (C2-C9)heteroaryl groups include furyl, thienyl, thiazolyl, pyrazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyrrolyl, triazolyl, tetrazolyl, imidazolyl, 1,3,5-oxadiazolyl,
1.2.4- oxadiazoIyl, 1,2,3-oxadiazolyl, 1,3,5-thiadiazolyl, 1,2,3-thiadiazolyl,
1.2.4- thiadiazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, 1,2,4-triazinyl,
1,2,3-triazinyl, 1,3,5-triazinyl, pyrazolo[3,4-b]pyridinyl, cinnolinyl, pteridinyl, purinyl,
6,7-dihydro-5H-[l]pyrindinyl, benzo[b]thiophenyl, 5,6,7,8-tetrahydro-quinolin-3-yl, benzoxazolyl, benzothiazolyl, benzisothiazolyl, benzisoxazolyl, benzimidazolyl, thianaphthenyl, isothianaphthenyl, benzofuranyl, isobenzofuranyl, isoindolyl, indolyl, indolizinyl, indazolyl, isoquinolyl, quinolyl, phthalazinyl, quinoxalinyl, quinazolinyl and benzoxazinyl, etc. The (C2-C9)heteroaryl group is typically attached to the main structure via a carbon atom, however, those of skill in the art will realize when certain other atoms, for example, hetero ring atoms, can be attached to the main structure. Other (C2-C9)heteroaryl groups will be readily apparent to those of skill in the art given the benefît of the présent disclosure.
«C
As used herein, the term “alkyl amine” means an (Ci-Cio)alkyl containing a primary, secondary, or tertiary amine group in place of one hydrogen atom, represented by (Ci-Cio)alkyl amine and ((Ci-Cio)alkyl)2 amine.
The term “alkyl ester” means a (Ci-Cio)alkyl containing an ester group in place of one hydrogen atom, represented by-0(0)C-(Ci-Cio)alkyl,
The term “alkyl acid” means an (Ci-Cio)alkyl containing a carboxylic acid group in place of one hydrogen atom, represented by (Ci-Cio)alkyl-COOH.
The term “aliphatic acid” means an acid of nonaromatic hydrocarbons, represented by (Ci-Cio)alkyl-COOH and (C3-Cio)cycloalkyl-COOH.
The term “halo” means a fluorine (F), chlorine (Cl), bromine (Br), iodine (I), or astatine (At) ion.
The term “methoxy” means a (Ci)alkyl containing an oxygen in place of one hydrogen atom, represented by -(0)0¾.
The term “polyol” means an alcohol containing multiple hydroxyl (-OH) groups.
“Substituted” means the substitution of a carbon in alkyl, heterocyclic or aryl groups with one or more non-carbon substituent. Non-carbon substituents are selected from nitrogen, oxygen and sulfiir.
“Unsubstituted” means the group is comprised of only hydrogen and carbon.
The term “polymer” means a molécule with a molecular weight over 1,000 Daltons comprised of one or more repeat units. The term “repeat unit” or “monomer” means a group in a polymer that repeats or appears multiple times in a polymer. Exemplary polymers include but are not limited to polyethylene, polyacrylamides, polymethacrylamides, polyacrylates, polymethacrylates, proteins, carbohydrates, polyvinylamine, and polyallylamine. Other polymers will be readily apparent to those of skill in the art given the benefit of the présent disclosure.
The term “co-polymer” means a polymer with two or more repeat units where the repeat units or “comonomers” are chemically and structurally different from one another. Exemplary co-polymers include but are not limited to ethylene-vinylacetate, styreneacrylonitrile, and styrene-isoprene-styrene. Other co-polymers will be readily apparent to those of skill in the art given the benefit of the présent disclosure.
The term “pharmaceutically acceptable anion” means an anion that is suitable for pharmaceutical use. Pharmaceutically acceptable anions include but are not limited to chloride, bromide, iodide, carbonate, bicarbonate, sulfate, nitrate, phosphate, acetate,
Yc ascorbate, benzoate, citrate, dihydrogen citrate, hydrogen citrate, oxalate, succinate, tartrate, taurocholate, glycocholate, cholate, fumarate, lactate, malate, tosylate, valerate, mucate, diphosphate and maleate.
A “guanidino group” is represented by Formula (A):
H
wherein a is an integer from 0 to 25,
A “guanidinium chloride group” is represented by Formula (B),
wherein b is an integer from 0 to 25,
A “guanidinobenzene group” is represented by Formula (C),
wherein c is an integer from 0 to 25,
A “dihydroxy group” is represented by Formula (D),
wherein d is an integer from 0 to 25, or
A “polyethylene glycol group” (PEG) is represented by Formula (E)
wherem e is an integer from 1 to 400.
The term “dicarbonyl refers to an organic molécule containing two or more adjacent carbonyl groups. Carbonyl groups, represented by C=O, can be, for example, aldéhydes, ketones, and other groups with an oxygen atom doubly bonded to a carbon atom. Examples include but are not limited to glyoxal, methylglyoxal, dimethyl glyoxal, and 3-deoxyglucosone.
The term “pharmaceutically acceptable end group” means an end group that is suitable for pharmaceutical use. Examples of pharmaceutically acceptable end groups include but are not limited to H, (Ci-Cio)alkyl, (C2-C9)heteroalkyl, (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (Cô-Cujaryl, (C2-C9)heteroaryl, (Ci-Cio)alkylamine, -0(0)C-(Ci-Cio)alkyl, (Ci-Cio)alkyl-COOH, (C3-Cio)cycloalkylCOOH, -(OjCEb, -OH, amide, a guanidino group, a guanidinium chloride group, a guanidinobenzene group, a dihydroxy group, and a polyethylene glycol group.
Related Art
Not applicable
BRIEF SUMMARY OF THE INVENTION
One aspect of the invention relates to a pharmaceutical composition comprising a compound, wherein the compound comprises the structure of Formula I:
wherein:
nis 0, 1, or 2;
o is 0,1, or 2;
x is an integer from 2 to 25,000;
R1 and R2 are each independently a pharmaceutically acceptable end group, a polymer, or -Rx-polymer, wherein Rx is selected from (Ci-Cio)alkyl, (C2-C9)heteroalkyl, (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (C6-Ci4)aryl, (C2-C9)heteroaryl, (Ci-Cio)alkylamine, -0(0)C-(Ci-Cio)alkyl, (Ci-Cio)alkyl-COOH, (C3-Cio)cycloalkyl-COOH, -(O)CH3, -OH, amide;
R3 and R4 are each independently H, a polymer, or -Rx-polymer, wherein Rx is selected from (Ci-Cio)alkyl, (C2-C9)heteroalkyl, (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (C6-Ci4)aryl, (C2-C9)heteroaryl, (Ci-Cio)alkylamine, -0(0)C-(Ci-Cio)alkyl, (Ci-Cio)alkyl-COOH, (C3-Cio)cycloalkyl-COOH, -(O)CH3, -OH, amide, or if n is 0 R4 is absent, and if o is 0 R3 is absent; and
R5 and R6 are each independently H, (Ci-Cio)alkyl, (C2-C9)heteroalkyl, (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (Cô-Ci4)aryl, (C2-C9)heteroaryl, (Ci-Cio)alkylamine, -0(0)C-(Ci-Cio)alkyl, (Ci-Cio)alkyl-COOH, (C3-Cio)cycloalkyl-COOH, -(O)CH3, -OH, NH2, -NH(Ci-Cio)alkyl, -N[(Ci-Cio)alkyl]2, or
R5 and R6 are taken together with the nitrogens to which they are attached to form a 6 to 20 member ring.
In one aspect of the invention, it is directed to a pharmaceutical composition comprising a compound, wherein the compound comprises the structure of Formula I-A:
wherein:
n is 0,1, or 2;
o is 0, 1, or 2;
x is an integer from 2 to 25,000;
Y' is each independently a pharmaceutically acceptable anion;
R1 and R2 are each independently a pharmaceutically acceptable end group, a polymer, or -Rx-polymer, wherein Rx is selected from (Ci-Cio)alkyl, (C2-C9)heteroalkyl, (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (C6-Ci4)aryl, (C2-C9)heteroaryl, (Ci-Cio)alkylamine, -0(0)C-(Ci-Cio)alkyl, (Ci-Cio)alkyl-COOH, (C3-Cio)cycloalkyl-COOH, -(O)CH3, -OH, amide;
R3 and R4 are each independently H, a polymer, or -Rx-polymer, wherein Rx is selected from (Ci-Cio)alkyl, (C2-C9)heteroalkyl, (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (Cô-Ci4)aryl, (C2-C9)heteroaryl, (Ci-Cio)alkylamine, -0(0)C-(Ci-Cio)alkyl, (Ci-Cio)alkyl-COOH, (C3-Cio)cycloalkyl-COOH, -(O)CH3, -OH, amide, or if n is 0 R4 is absent, and if o is 0 R3 is absent; and
R5 and R6 are each independently H, (Ci-Cio)alkyl, (C2-C9)heteroalkyl, (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (C6-Ci4)aryl, (C2-C9)heteroaryl, (Ci-Cio)alkylamine, -0(0)C-(Ci-Cio)alkyl, (Ci-Cio)alkyl-COOH, (C3-Cio)cycloalkyl-COOH, -(O)CH3, -OH, NH2, -NH(Ci-Cio)alkyl, -N[(Ci-Cio)alkyl]2 or
R5 and R6 are taken together with the nitrogens to which they are attached to form a 6 to 20 member ring.
Another aspect of the invention relates to a pharmaceutical composition comprising a compound, wherein the compound comprises the structure of Formula II:
(Π) wherein:
m is 0, 1, or 2;
&L
R7 and R8 are each independently a pharmaceutically acceptable end group or a polymer, -Rx-polymer, wherein Rx is selected from (Ci-Cio)alkyl, (C2-C9)heteroalkyl, (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (C6-Ci4)aryl, (C2-C9)heteroaryl, (Ci-Cio)alkylamine, -0(0)C-(Ci-Cio)alkyl, (Ci-Cio)alkyl-COOH, (C3-Cio)cycloalkyl-COOH, -(O)CH3, -OH, amide, or
R7 and R8 are taken together with the carbons to which they are attached to form a 3 to 10 member ring, wherein the 3 to 10 member ring is optionally attached to a polymer or substituted by one to four groups selected from (CiCio)alkyl, (C2-C9)heteroalkyl, (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (C6-Ci4)aryl, (C2-C9)heteroaryl, (Ci-Cio)alkylamine, -0(0)C-(Ci-Cio)alkyl, (Ci-Cio)alkyl-COOH, (C3-Cio)cycloalkyl-COOH, -(O)CH3, -OH, amide or -Ry-polymer, wherein Ry is selected from (Ci-Cio)alkyl, (C2C9)heteroalkyl, (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (C6-Ci4)aryl, (C2-C9)heteroaryl, (C i -C i o)alkylamine, -O(O)C-(C i -C io)alkyl, (Ci-Cio)alkyl-COOH, (C3-Cio)cycloalkyl-COOH, -(O)CH3, -OH, or amide;
R9 is H, a group selected from (Ci-Cio)alkyl, (C2-C9)heteroalkyl, (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (C6-Ci4)aryl, (C2-C9)heteroaryl, (Ci-Cio)alkylamine, -0(0)C-(Ci-Cio)alkyl, (Ci-Cio)alkyl-COOH, (C3-Cio)cycloalkyl-COOH, -(O)CH3, -OH, amide, a polymer, or -Ry-polymer, wherein Ry is selected from (Ci-Cio)alkyl, (C2-C9)heteroalkyl, (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (C6-Ci4)aryl, (C2-C9)heteroaryl, (Ci-Cio)alkylamine, -0(0)C-(Ci-Cio)alkyl, (Ci-Cio)alkyl-COOH, (C3-Cio)cycloalkyl-COOH, -(O)CH3, -OH, or amide, or if m is 0, R9 is absent; and tet
R10 and R11 are each independently H, (Ci-Cio)alkyl, (C2-C9)heteroalkyl, (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (C6-Ci4)aryl, (C2-C9)heteroaryl, (Ci-Cio)alkylamine, -0(0)C-(Ci-Cio)alkyl, (Ci-Cio)alkyl-COOH, (C3-Cio)cycloalkyl-COOH, -(O)CH3, -OH, NH2, -NH(Ci-Cio)alkyl, -N[(Ci-Cio)alkyl]2 or
R10 and R11 are taken together with the nitrogens to which they are attached to form a 6 to 20 member ring.
Yet another aspect of the invention relates to a pharmaceutical composition comprising a compound, wherein the compound comprises the structure of Formula II-A:
(II-A) wherein:
m is 0, 1, or 2;
Y is each independently a pharmaceutically acceptable anion;
R7 and R8 are each independently a pharmaceutically acceptable end group or a polymer, -Rx-polymer, wherein Rx is selected from (Ci-Cio)alkyl, (C2-C9)heteroalkyl, (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (C6-Ci4)aryl, (C2-C9)heteroaryl, (Ci-Cio)alkylamine, -0(0)C-(Ci-Cio)alkyl, (Ci-Cio)alkyl-COOH, (C3-Cio)cycloalkyl-COOH, -(O)CH3, -OH, amide, or
R7 and R8 are taken together with the carbons to which they are attached to form a 3 to 10 member ring, wherein the 3 to 10 member ring is optionally attached to a polymer or substituted by one to four groups selected from (CiCio)alkyl, (C2-C9)heteroalkyl, (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (C6-Ci4)aryl, (C2-C9)heteroaryl, h
(Ci-Cio)alkylamine, -0(0)C-(Ci-Cio)alkyl> (Ci-Cio)alkyl-COOH, (C3-Cio)cycloalkyl-COOH, -(0)(¾ -OH, amide or-Ry-polymer, wherein Ry is selected from (Ci-Cio)alkyl, (C2Cçjheteroalkyl, (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (Ce-Cujaryl, (C2-C9)heteroaryl, (Ci -C i o)alkylamine, -O(O)C-(C i -C i o)alkyl, (Ci-Cio)alkyl-COOH, (C3-Cio)cycloalkyl-COOH, -(O)CH3, -OH, or amide; and
R9 is H, a group selected from (Ci-Cio)alkyl, (C2-C9)heteroalkyl, (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (C6-Ci4)aryl, (C2-C9)heteroaryl, (Ci-Cio)alkylamine, -0(0)C-(Ci-Cio)alkyl, (Ci-Cio)alkyl-COOH, (C3-Cio)cycloalkyl-COOH, -(O)CH3, -OH, amide, a polymer, or -Ry-polymer, wherein Ry is selected from (Ci-Cio)alkyl, (C2-C9)heteroalkyl, (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (C6-Ci4)aryl, (C2-C9)heteroaryl, (Ci-Cio)alkylamine, -0(0)C-(Ci-Cio)alkyl, (Ci-Cio)alkyl-COOH, (C3-Cio)cycloalkyl-COOH, -(O)CH3, -OH, or amide, or if m is 0, R9 is absent; and
R10 and R11 are each independently H, (Ci-Cio)alkyl, (C2-C9)heteroalkyl, (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (C6-Ci4)aryl, (C2-C9)heteroaryl, (Ci-Cio)alkylamine, -0(0)C-(Ci-Cio)alkyl, (Ci-Cio)alkyl-COOH, (C3-Cio)cycloalkyl-COOH, -(O)CH3, -OH, NH2, -NH(Ci-Cio)alkyl, -N[(Ci-Cio)alkyl]2 or
R10 and R11 are taken together with the nitrogens to which they are attached to form a 6 to 20 member ring.
In another aspect, the invention relates to a method of binding AGE precursors in a mammal comprising administering to the patient a pharmaceutical composition comprising a compound according to Formula I. In yet another aspect, the invention relates to a method of binding AGE precursors in a mammal comprising administering to the patient a pharmaceutical composition comprising a compound according to Formula
I-A. In another aspect, the invention relates to a method of binding AGE precursors in a mammal comprising administering to the patient a pharmaceutical composition comprising a compound according to Formula IL In yet another aspect, the invention relates to a method of binding AGE precursors in a mammal comprising administering to the patient a pharmaceutical composition comprising a compound according to Formula II-A.
In another aspect, the invention relates to a method of binding dietary dicarbonyls in a mammal comprising administering to the patient a pharmaceutical composition comprising a compound according to Formula I. In yet another aspect, the invention relates to a method of binding dietary dicarbonyls in a mammal comprising administering to the patient a pharmaceutical composition comprising a compound according to Formula I-A. In another aspect, the invention relates to a method of binding dietary dicarbonyls in a mammal comprising administering to the patient a pharmaceutical composition comprising a compound according to Formula II. In yet another aspect, the invention relates to a method of binding dietary dicarbonyls in a mammal comprising administering to the patient a pharmaceutical composition comprising a compound according to Formula II-A.
Brief Description of the Several Views of the Drawing(s)
Not applicable
Detailed Description of the Invention
This invention relates to novel séquestrants of advanced glycation end products (AGE) precursors. The séquestrants of AGE precursors are of varying structures and comprise amine groups.
Advanced glycation end products are modified proteins and protein dérivatives that are formed by the reaction of amino acid side chain functional groups, including but not limited to amine groups and guanidinium groups, with dicarbonyl compounds. Dicarbonyl compounds are présent in foods, are formed during digestion, or are produced in the body through various biochemical processes. Dicarbonyls présent in foods or formed in the gut during digestion can be absorbed into the body where they can react with proteins to form AGE. It is an object of the présent invention to prevent that absorption by reacting the dicarbonyls présent in the gastrointestinal tract to the materials of the présent invention, causing them to be safely excreted in the feces before they can be absorbed.
AGE are formed by the reaction of dicarbonyl compounds with amino acid side chains of proteins through the Maillard reaction. The pendant amino groups of lysine residues of a protein react with carbonyl compounds to form a Schiff base. The Schiff base, under physiological conditions, transforms through a process called Amadori rearrangements. Dicarbonyls also react with arginine and other amine- and guanidinecontaining biomolecules through analogous processes. The resulting compounds, AGE, are toxic due to protein crosslinking, among other toxic mechanisms. Structures of several dicarbonyl compounds in foods, or formed either by digestion and/or biological oxidation/peroxidation are shown in Erreur ! Source du renvoi introuvable..
Formation of AGE is accelerated by metabolic diseases such as chronic kidney disease (CKD). Formation and accumulation of AGE in the plasma and tissue lead to a number of disorders of cardiovascular and rénal complications including atherosclerosis, and diabetic nephropathy. The présent invention addresses a novel approach to suppress the formation of AGE by selectively removing the dietary dicarbonyls and endogenous dicarbonyls found in food or produced in the gut using appropriate séquestrants of AGE precursors. The séquestrants of AGE precursors bind the carbonyl compounds through chemoselective reactions. These high molecular weight séquestrants of AGE precursors (preferably polymers that are crosslinked or non-crosslinked) are biostable and systemically non-absorbed. As a resuit, the sequestered dicarbonyls are removed through fecal excrétion. The séquestrants of AGE precursors of the présent invention can be soluble high molecular weight polymers and crosslinked polymer hydrogels compositions containing amine groups. The invention discloses that these materials are useful as therapeutically significant agents to sequester dicarbonyl compounds in the GI tract for the treatment of a number of ailments such as diabetic nephropathy, chronic rénal disease, atherosclerosis, stroke, cataracts, and Alzheimer’s disease.
The séquestrants of AGE precursors contain amine groups separated by 2, 3 or 4 carbons. The amine groups may be primary, secondary or tertiary amines. The séquestrants of AGE precursors can be small molécules or polymers. If the séquestrants of AGE precursors are polymers, they may be a polymer or copolymer and the amine groups may be on the polymer backbone or pendant from the polymer backbone.
The séquestrants of AGE precursors of the présent invention are of varying molecular weights.
te
The séquestrants of AGE precursors bind diet derived dicarbonyl compounds in the gastrointestinal tract. The sequestered dicarbonyls are removed through fecal excrétion.
This invention relates to pharmaceutical compositions comprising séquestrants of AGE precursors. This invention also relates to methods of binding AGE precursor compounds and method of binding dietary dicarbonyls with séquestrants of AGE precursors. The séquestrants of AGE precursors and the pharmaceutical compositions comprising séquestrants of AGE precursors can be administered in multiple dosage forms.
One embodiment of the présent invention relates to séquestrants of AGE precursors comprising a compound with the structure of Formula I:
wherein:
n is 0,1, or 2;
o is 0,1, or 2;
x is an integer from 2 to 25,000;
R1 and R2 are each independently a pharmaceutically acceptable end group, a polymer, or -Rx-polymer, wherein Rx is selected from (Ci-Cio)alkyl, (C2-C9)heteroalkyl, (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (C6-Ci4)aryl, (C2-C9)heteroaryl, (Ci-Cio)alkylamine, -0(0)C-(Ci-Cio)alkyl, (Ci-Cio)alkyl-COOH, (C3-Cio)cycloalkyl-COOH, -(O)CH3, -OH, amide;
R3 and R4 are each independently H, a polymer, or -Rx-polymer, wherein Rx is selected from (Ci-Cio)alkyl, (C2-C9)heteroalkyl, (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (C6-Ci4)aryl, (C2-C9)heteroaryl, (Ci-Cio)alkylamine, -0(0)C-(Ci-Cio)alkyl, (Ci-Cio)alkyl-COOH, (C3-Cio)cycloalkyl-COOH, -(O)CH3, -OH, amide, or if n is 0 R4 is absent, and if o is 0 R3 is absent; and
R5 and R6 are each independently H, (Ci-Cio)alkyl, (C2-C9)heteroalkyl, (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (C6-Ci4)aryl, (C2-C9)heteroaryl, (Ci-Cio)alkylamine, -0(0)C-(Ci-Cio)alkyl, (Ci-Cio)alkyl-COOH, (C3-Cio)cycloalkyl-COOH, -(O)CH3, -OH, NH2, -NH(Ci-Cio)alkyl, -N[(Ci-Cio)alkyl]2 or
R5 and R6 are taken together with the nitrogens to which they are attached to form a 6 to 20 member ring.
Another embodiment of the présent invention relates to séquestrants of AGE precursors wherein the compound comprises the structure of Formula I-A:
wherein:
n is 0,1, or 2;
o is 0,1, or 2;
x is an integer from 2 to 25,000;
Y’ is each independently a pharmaceutically acceptable anion;
R1 and R2 are each independently a pharmaceutically acceptable end group, a polymer, or -Rx-polymer, wherein Rx is selected from (Ci-Cio)alkyl, (C2-C9)heteroalkyl, (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (C6-Ci4)aryl, (C2-C9)heteroaryl, (Ci-Cio)alkylamine, -0(0)C-(Ci-Cio)alkyl, (Ci-Cio)alkyl-COOH, (C3-Cio)cycloalkyl-COOH, -(O)CH3, -OH, amide;
R3 and R4 are each independently H, a polymer, or -Rx-polymer, wherein Rx is selected from (Ci-Cio)alkyl, (C2-C9)heteroalkyl, (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (C6-Ci4)aryl, (C2-C9)heteroaryl, (Ci-Cio)alkylamine, -0(0)C-(Ci-Cio)alkyl, (Ci-Cio)alkyl-COOH, (C3-Cio)cycloalkyl-COOH, -(O)CH3, -OH, amide, or if n is 0 R4 is absent, and if o is 0 R3 is absent; and
R5 and R6 are each independently H, (Ci-Cio)alkyl, (C2-C9)heteroalkyl, (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (C6-Ci4)aryl, (C2-C9)heteroaryl, (Ci-Cio)alkylamine, -0(0)C-(Ci-Cio)alkyl, (Ci-Cio)alkyl-COOH, (C3-Cio)cycloalkyl-COOH, -(O)CH3, -OH, NH2, -NH(Ci-Cio)alkyl, -N[(Ci-Cio)alkyl]2 or
R5 and R6 are taken together with the nitrogens to which they are attached to form a 6 to 20 member ring.
Another embodiment of the présent invention relates to séquestrants of AGE precursors wherein the compound comprises the structure of Formula II: (II)
(II) wherein:
m is 0, 1, or 2;
R7 and R8 are each independently a pharmaceutically acceptable end group or a polymer, -Rx-polymer, wherein Rx is selected from (Ci-Cio)alkyl, (C2-C9)heteroalkyl, (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (C6-Ci4)aryl, (C2-C9)heteroaryl, (Ci-Cio)alkylamine, -0(0)C-(Ci-Cio)alkyl, (Ci-Cio)alkyl-COOH, (C3-Cio)cycloalkyl-COOH, -(O)CH3, -OH, amide, or
R7 and R8 are taken together with the carbons to which they are attached to form a 3 to 10 member ring, wherein the 3 to 10 member ring is optionally attached to a polymer or substituted by one to four groups selected from (CiCio)alkyl, (C2-C9)heteroalkyl, (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (Cô-Ci4)aryl, (C2-C9)heteroaryl, (Ci-Cio)alkylamine, -0(0)C-(Ci-Cio)alkyl, (Ci-Cio)alkyl-COOH, (C3-Cio)cycloalkyl-COOH, -(O)CH3, -OH, amide or-Ry-polymer, wherein Ry is selected from (Ci-Cio)alkyl, (C2C9)heteroalkyl, (C3-C1 o)cycloalkyl, (C2-C9)heterocycloalkyl, (C6-Ci4)aryl, (C2-C9)heteroaryl, (Ci-Cio)alkylamine, -0(0)C-(Ci-Cio)alkyl, (Ci-Cio)alkyl-COOH, (C3-Cio)cycloalkyl-COOH, -(O)CH3, -OH, or amide;
R9 is H, a group selected from (Ci-Cio)alkyl, (C2-C9)heteroalkyl, (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (C6-Ci4)aryl, (C2-C9)heteroaryl, (Ci-Cio)alkylamine, -0(0)C-(Ci-Cio)alkyl, (Ci-Cio)alkyl-COOH, (C3-Cio)cycloalkyl-COOH, -(O)CH3, -OH, amide, a polymer, or -Ry-polymer, wherein Ry is selected from (Ci-Cio)alkyl, (C2-C9)heteroalkyl, (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (C6-Ci4)aryl, (C2-C9)heteroaryl, (Ci-Cio)alkylamine, -0(0)C-(Ci-Cio)alkyl, (Ci-Cio)alkyl-COOH, (C3-Cio)cycloalkyl-COOH, -(O)CH3, -OH, or amide, or if m is 0, R9 is absent; and
R10 and R11 are each independently H, (Ci-Cio)alkyl, (C2-C9)heteroalkyl, (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (C6-Ci4)aryl, (C2-C9)heteroaryl, (Ci-Cio)alkylamine, -0(0)C-(Ci-Cio)alkyl, (Ci-Cio)alkyl-COOH, (C3-Cio)cycloalkyl-COOH, -(O)CH3, -OH, NH2, -NH(Ci-Cio)alkyl, -N[(Ci-Cio)alkyl]2 or
R10 and R11 are taken together with the nitrogens to which they are attached to form a 6 to 20 member ring.
Another embodiment of the présent invention is directed to séquestrants of AGE precursors wherein the compound comprises the structure of Formula II-A:
(II-A) wherein:
m is 0,1, or 2;
Y' is each independently a pharmaceutically acceptable anion;
R7 and R8 are each independently a pharmaceutically acceptable end group or a polymer, -Rx-polymer, wherein Rx is selected from (Ci-Cio)alkyl, (C2-C9)heteroalkyl, (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (C6-Ci4)aryl, (C2-C9)heteroaryl, (Ci-Cio)alkylamine, -0(0)C-(Ci-Cio)alkyl, (Ci-Cio)alkyl-COOH, (C3-Ci0)cycloalkyl-COOH, -(O)CH3, -OH, amide, or
R7 and R8 are taken together with the carbons to which they are attached to form a 3 to 10 member ring, wherein the 3 to 10 member ring is optionally attached to a polymer or substituted by one to four groups selected from (CiCio)alkyl, (C2-C9)heteroalkyl, (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (Cô-Cujaryl, (C2-C9)heteroaryl, (Ci-Cio)alkylamine, -O(O)C-(Ci-Ci0)alkyl, (Ci-Cio)alkyl-COOH, (C3-Cio)cycloalkyl-COOH, -(0)0¾ -OH, amide or -Ry-polymer, wherein Ry is selected from (Ci-Cio)alkyl, (C2C9)heteroalkyl, (C3-C1 o)cycloalkyl, (C2-C9)heterocycloalkyl, (C6-Ci4)aryl, (C2-C9)heteroaryl, (Ci-Cio)alkylamine, -0(0)C-(Ci-Cio)alkyl, (Ci-Cio)alkyl-COOH, (C3-Ci0)cycloalkyl-COOH, -(O)CH3, -OH, or amide; and
R9 is H, a group selected from (Ci-Cio)alkyl, (C2-C9)heteroalkyl, (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (C6-Ci4)aryl, (C2-C9)heteroaryl, (Ci-Cio)alkylamine, -0(0)C-(Ci-Cio)alkyl, (Ci-Cio)alkyl-COOH, (C3-Cio)cycloalkyl-COOH, -(O)CH3, -OH, amide, a polymer, or -Ry-polymer, wherein Ry is selected from (Ci-Cio)alkyl, (C2-C9)heteroalkyl, (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (C6-Ci4)aryl, (C2-C9)heteroaryl, (Ci-Cio)alkylamine, -0(0)C-(Ci-Cio)alkyl, (Ci-Cio)alkyl-COOH, (C3-Cio)cycloalkyl-COOH, -(O)CH3, -OH, or amide, or if m is 0, R9 is absent; and
R10 and R11 are each independently H, (Ci-Cio)alkyl, (C2-C9)heteroalkyl, (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (C6-Ci4)aryl, (C2-C9)heteroaryl, (Ci-Cio)alkylamine, -0(0)C-(Ci-Cio)alkyl, (Ci-Cio)alkyl-COOH, (C3-Cio)cycloalkyl-COOH, -(O)CH3, -OH, NH2, -NH(Ci-Cio)alkyl, -N[(Ci-Cio)alkyl]2 or
R10 and R11 are taken together with the nitrogens to which they are attached to form a 6 to 20 member ring.
In one embodiment this invention comprises to a method of binding AGE precursors in a mammal comprising administering a pharmaceutical composition comprising a séquestrant of AGE precursors, wherein the séquestrant of AGE precursors comprises a compound with the structure of Formula I, Formula I-A, Formula II or Formula II-A.
In another embodiment this invention comprises to a method of binding dietary dicarbonyls in a mammal comprising administering a pharmaceutical composition comprising a séquestrant of AGE precursors, wherein the séquestrant of AGE precursors comprises a compound with the structure of Formula I, Formula I-A, Formula II or Formula II-A.
In another embodiment of the invention, the séquestrants of AGE precursors are the active pharmaceutical ingrédient in a pharmaceutical composition. In a preferred embodiment of the invention, the pharmaceutical composition comprises a compound, wherein the compound comprises the structure of Formula I:
übl
wherein:
n is 0, 1, or 2;
o is 0,1, or 2;
x is an integer from 2 to 25,000;
R1 and R2 are each independently a pharmaceutically acceptable end group, a polymer, or -Rx-polymer, wherein Rx is selected from (Ci-Cio)alkyl, (C2-Cç))heteroalkyl, (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (C6-Ci4)aryl, (C2-C9)heteroaryl, (Ci-Cio)alkylamine, -0(0)C-(Ci-Cio)alkyl, (Ci-Cio)alkyl-COOH, (C3-Cio)cycloalkyl-COOH, -(O)CH3, -OH, amide;
R3 and R4 are each independently H, a polymer, or -Rx-polymer, wherein Rx is selected from (Ci-Cio)alkyl, (C2-C9)heteroalkyl, (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (C6-Ci4)aryl, (C2-C9)heteroaryl, (Ci-Cio)alkylamine, -0(0)C-(Ci-Cio)alkyl, (Ci-Cio)alkyl-COOH, (C3-Cio)cycloalkyl-COOH, -(O)CH3, -OH, amide, or if n is 0 R4 is absent, and if o is 0 R3 is absent; and
R5 and R6 are each independently H, (Ci-Cio)alkyl, (C2-C9)heteroalkyl, (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (C6-Ci4)aryl, (C2-C9)heteroaryl, (Ci-Cio)alkylamine, -0(0)C-(Ci-Cio)alkyl, (Ci-Cio)alkyl-COOH, (C3-Cio)cycloalkyl-COOH, -(O)CH3, -OH, NH2, -NH(Ci-Cio)alkyl, -N[(Ci-Cio)alkyl]2 or
R5 and R6 are taken together with the nitrogens to which they are attached to form a 6 to 20 member ring.
In another preferred embodiment of the invention, the pharmaceutical composition comprises a compound, wherein the compound comprises the structure of Formula I-A:
wherein:
n is 0, 1, or 2;
o is 0,1, or 2;
x is an integer from 2 to 25,000;
Y' is each independently a pharmaceutically acceptable anion;
R1 and R2 are each independently a pharmaceutically acceptable end group, a polymer, or -Rx-polymer, wherein Rx is selected from (Ci-Cio)alkyl, (C2-C9)heteroalkyl, (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (C6-Ci4)aryl, (C2-C9)heteroaryl, (Ci-Cio)alkylamine, -0(0)C-(Ci-Cio)alkyl, (Ci-Cio)alkyl-COOH, (C3-Cio)cycloalkyl-COOH, -(O)CH3, -OH, amide;
R3 and R4 are each independently H, a polymer, or -Rx-polymer, wherein Rx is selected from (Ci-Cio)alkyl, (C2-C9)heteroalkyl, (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (C6-Ci4)aryl, (C2-C9)heteroaryl, (Ci-Cio)alkylamine, -0(0)C-(Ci-Cio)alkyl, (Ci-Cio)alkyl-COOH, (C3-Cio)cycloalkyl-COOH, -(O)CH3, -OH, amide, or if n is 0 R4 is absent, and if o is 0 R3 is absent; and
R5 and R6 are each independently H, (Ci-Cio)alkyl, (C2-C9)heteroalkyl, (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (C6-Ci4)aryl, (C2-C9)heteroaryl, (Ci-Cio)alkylamine, -0(0)C-(Ci-Cio)alkyl,
Ç>L (Ci-Cio)alkyl-COOH, (C3-Cio)cycloalkyl-COOH, -(O)CH3, -OH, NH2, -NH(Ci-Cio)alkyl, -N[(Ci-Cio)alkyl]2 or
R5 and R6 are taken together with the nitrogens to which they are attached to form a 6 to 20 member ring.
In another embodiment of the invention the séquestrants of AGE precursors are the active pharmaceutical ingrédient in a pharmaceutical composition. In a preferred embodiment of the invention, the pharmaceutical composition comprises a compound, wherein the compound comprises the structure of Formula II:
(H) wherein:
m is 0, 1, or 2;
R7 and R8 are each independently a pharmaceutically acceptable end group or a polymer, -Rx-polymer, wherein Rx is selected from (Ci-Cio)alkyl, (C2-C9)heteroalkyl, (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (C6-Ci4)aryl, (C2-C9)heteroaryl, (Ci-Cio)alkylamine, -0(0)C-(Ci-Cio)alkyl, (Ci-Cio)alkyl-COOH, (C3-Cio)cycloalkyl-COOH, -(O)CH3, -OH, amide, or
R7 and R8 are taken together with the carbons to which they are attached to form a 3 to 10 member ring, wherein the 3 to 10 member ring is optionally attached to a polymer or substituted by one to four groups selected from (CiCio)alkyl, (C2-C9)heteroalkyl, (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (C6-Ci4)aryl, (C2-C9)heteroaryl, (Ci-Cio)alkylamine, -O(O)C-(Ci-Ci0)alkyl, (Ci-Cio)alkyl-COOH, (C3-Cio)cycloalkyl-COOH, -(O)CH3, -OH, amide or —Ry-polymer, »
wherein Ry is selected from (Ci-Cio)alkyl, (C2Cç))heteroalkyl, (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (C6-Ci4)aryl, (C2-C9)heteroaryl, (C i -C io)alkylamine, -O(O)C-(C 1 -C 1 o)alkyl, (Ci-Cio)alkyl-COOH, (C3-Cio)cycloalkyl-COOH, -(O)CH3, -OH, or amide;
R9 is H, a group selected from (Ci-Cio)alkyl, (C2-C9)heteroalkyl, (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (C6-Ci4)aryl, (C2-C9)heteroaryl, (Ci-Cio)alkylamine, -0(0)C-(Ci-Cio)alkyl, (Ci-Cio)alkyl-COOH, (C3-Cio)cycloalkyl-COOH, -(O)CH3, -OH, amide, a polymer, or -Ry-polymer, wherein Ry is selected from (Ci-Cio)alkyl, (C2-C9)heteroalkyl, (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (C6-Ci4)aryl, (C2-C9)heteroaryl, (Ci-Cio)alkylamine, -0(0)C-(Ci-Cio)alkyl, (Ci-Cio)alkyl-COOH, (C3-Cio)cycloalkyl-COOH, -(O)CH3, -OH, or amide, or if m is 0, R9 is absent; and
R10 and R11 are each independently H, (Ci-Cio)alkyl, (C2-C9)heteroalkyl, (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (C6-Ci4)aryl, (C2-C9)heteroaryl, (Ci-Cio)alkylamine, -0(0)C-(Ci-Cio)alkyl, (Ci-Cio)alkyl-COOH, (C3-Cio)cycloalkyl-COOH, -(O)CH3, -OH, NH2, -NH(C1-Cio)alkyl, -N[(Ci-Cio)alkyl]2 or
R10 and R11 are taken together with the nitrogens to which they are attached to form a 6 to 20 member ring.
In another embodiment of the invention, the séquestrants of AGE precursors are the active pharmaceutical ingrédient in a pharmaceutical composition. In a preferred embodiment of the invention, the pharmaceutical composition comprises a compound, wherein the compound comprises the structure of Formula II-A:
«C
R9 is H, a group selected from (Ci-Cio)alkyl, (C2-C9)heteroalkyl, (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (Cô-Ci4)aryl, (C2-C9)heteroaryl, (Ci-Cio)alkylamine, -0(0)C-(Ci-Cio)alkyl, (Ci-Cio)alkyl-COOH, (C3-Cio)cycloalkyl-COOH, -(O)CH3, -OH, amide, a polymer, or -Ry-polymer, wherein Ry is selected from (Ci-Cio)alkyl, (C2-C9)heteroalkyl, (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (C6-Ci4)aryl, (C2-C9)heteroaryl, (Ci-Cio)alkylamine, -0(0)C-(Ci-Cio)alkyl, (Ci-Cio)alkyl-COOH, (C3-Cio)cycloalkyl-COOH, -(O)CH3, -OH, or amide, or if m is 0, R9 is absent; and
R10 and R11 are each independently H, (Ci-Cio)alkyl, (C2-C9)heteroalkyl, (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (Cô-Ci4)aryl, (C2-C9)heteroaryl, (Ci-Cio)alkylamine, -0(0)C-(Ci-Cio)alkyl, (Ci-Cio)alkyl-COOH, (C3-Cio)cycloalkyl-COOH, -(O)CH3, -OH, NH2, -NH(Ci-Cio)alkyl, -N[(Ci-Cio)alkyl]2 or R10 and R11 are taken together with the nitrogens to which they are attached to form a 6 to 20 member ring.
In one embodiment of the invention, the séquestrants of AGE precursors are polymers. In some embodiments, the polymers may comprise a monomer comprising a compound having a repeat unit according to Formula I, Formula I-A, Formula II or Formula II-A. In other embodiments, the polymers may comprise a monomer comprising a compound having two or more repeat units, where the upper limit is not thought to be critical. Accordingly, the séquestrants of AGE precursors may comprise a monomer repeating two to over a million times, preferably two to 25,000. In one embodiment of the invention, the séquestrants of AGE precursors are copolymers. In some embodiments, the copolymers may comprise a monomer comprising a compound having at least one unit which is copolymerized with one or more other comonomers or oligomers or other polymerizable groups.
In preferred embodiments of the invention, the séquestrants of AGE precursors are a compound of Formula I or Formula I-A where n and o are both 0, and where n and o are both 1. In another preferred embodiment, the séquestrants of AGE precursors are a compound of Formula II or Formula II-A, where m is 0. In another preferred embodiment, the séquestrants of AGE precursors are polymers. In a preferred embodiment of the invention the séquestrant of AGE precursors of Formula I or Formula I-A are poly(vinylamine). In another preferred embodiment the séquestrants of AGE precursors of Formula I or Formula I-A are poly(methyleneamine). In another preferred embodiment, the séquestrants of AGE precursors of Formula II or Formula II-A are poly {2,3 -diamino {[3 - [(2-methyl-1 -oxo-2-propen-1 yl)amino]propyl]amino}propaneamide- co-ethylenebismethacrylamide}. In yet another preferred embodiment, the séquestrants of AGE precursors of Formula II or Formula II-A are poly(3,4-diaminostyrene-co-divinyl benzene).
In a preferred embodiment of the invention, R1 and R2 are each independently and R7 and R8 are each independently a pharmaceutically acceptable end group. In another preferred embodiment of the invention, R7 and R8 are each independently a pharmaceutically acceptable end group, a polymer, -Rx-polymer, wherem Rx is selected from (Ci-Cio)alkyl, (C2-C9)heteroalkyl, (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (CôCi4)aryl, (C2-C9)heteroaryl, (Ci-Cio)alkylamine, -0(0)C-(Ci-Cio)alkyl, (Ci-Cio)alkyl-COOH, (C3-Cio)cycloalkyl-COOH, -(O)CH3, -OH, amide, or R7 and R8 are taken together with the carbons to which they are attached to form a 3 to 10 member ring, wherein the 3 to 10 member ring is optionally attached to a polymer or substituted by one to four groups selected from (Ci-Cio)alkyl, (C2-C9)heteroalkyl, (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (C6-Ci4)aryl, (C2-C9)heteroaryl, (Ci-Cio)alkylamine, -0(0)C-(Ci-Cio)alkyl, (Ci-Cio)alkyl-COOH, (C3-Cio)cycloalkylCOOH, -(O)CH3, -OH, amide or -Ry-polymer, wherein Ry is selected from (Ci-Cio)alkyl, (C2-C9)heteroalkyl, (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (C6-Ci4)aryl, (C2-C9)heteroaryl, (Ci-Cio)alkylamine, -0(0)C-(Ci-Cio)alkyl, (Ci-Cio)alkyl-COOH, (C3-Cio)cycloalkyl-COOH, -(O)CH3, -OH, or amide.
In a more preferred embodiment, R1 and R2 are each independently and R7 and R8 are each independently H, a group selected from (Ci-Cio)alkyl, (C2-C9)heteroalkyl, (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (Cô-Ci4)aryl, (C2-C9)heteroaryl, (Ci-Cio)alkylamine, -O(O)C-(Ci-Ci0)alkyl, (Ci-Cio)alkyl-COOH, (C3-Cio)cycloalkyl-COOH, -(O)CH3, -OH, amide, a guanidino group, a guanidinium chloride, a guanidinobenzene group, a dihydroxy group, a polyethylene glycol group, a polymer, -Rx-polymer, wherein Rx is selected from (Ci-Cio)alkyl, (C2-C9)heteroalkyl,
M (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (C6-Ci4)aryl, (C2-C9)heteroaryl, (Ci-Cio)alkylamine, -0(0)C-(Ci-Cio)alkyl, (Ci-Cio)alkyl-COOH, (C3-Cio)cycloalkylCOOH, -(O)CH3, -OH, amide, or, R7 and R8, are taken together with the carbons to which they are attached to form a 3 to 10 member ring, wherein the 3 to 10 member ring is optionally attached to a polymer or substituted by one to four groups selected from (Ci-Cio)alkyl, (C2-C9)heteroalkyl, (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (Cf,-Ci4)aryl, (C2-C9)heteroaryl, (Ci-Cio)alkylamine, -0(0)C-(Ci-Cio)alkyl, (Ci-Cio)alkyl-COOH, (C3-Cio)cycloalkyl-COOH, -(O)CH3, -OH, amide or-R*-polymer, wherein Ry is selected from (Ci-Cio)alkyl, (C2-C9)heteroalkyl, (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (C6-Ci4)aryl, (C2-C9)heteroaryl, (CiCio)alkylamine, -0(0)C-(Ci-Cio)alkyl, (Ci-Cio)alkyl-COOH, (C3-Cio)cycloalkyl-COOH, -(O)CH3, -OH, or amide.
In a preferred embodiment of the invention, R5 and R6 are each independently and R10 and R11 are each independently H, (Ci-Cio)alkyl, (C2-C9)heteroalkyl, (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (C6-Ci4)aryl, (C2-C9)heteroaryl, (CiCio)alkylamine, -0(0)C-(Ci-Cio)alkyl, (Ci-Cio)alkyl-COOH, (C3-Cio)cycloalkyl-COOH, -(O)CH3, -OH, -NH2, -NH(Ci-Cio)alkyl, -N[(Ci-Cio)alkyl]2. In a more preferred embodiment, R5 and R6 are each independently and R10 and R11 are each independently H or (Ci-Cio)alkyl. In yet another preferred embodiment, R5 and R6 are each independently and R10 and R11 are each independently H or -CH3. In another preferred embodiment, R5 and R6 are each and R10 and R11 are each H.
In a preferred embodiment of the invention, R5 and R6 are taken together with the nitrogens to which they are attached and R10 and R11 are taken together with the nitrogens to which they are attached to form a 6 to 20 member ring. In a preferred embodiment, R5 and R6 are taken together with the nitrogens to which they are attached to form a 14 member ring. In another preferred embodiment, R10 and R11 are taken together with the nitrogens to which they are attached to form a 14 member ring.
In a preferred embodiment of the invention, Y' is a pharmaceutically acceptable anion. In another preferred embodiment, Y- is independently selected from carbonate, bicarbonate or chloride. In another preferred embodiment, Y- is independently selected from carbonate or bicarbonate. In another preferred embodiment, Y- is chloride.
In preferred embodiment, the séquestrants of AGE precursors of Formula I, Formula I-A, Formula II or Formula II-A are crosslinked polymers. The séquestrants of AGE precursors of Formula I, Formula I-A, Formula II or Formula II-A are crosslinked with epichlorohydrin, represented by Formula F.
O
Cl (F)
Non-limiting examples of suitable séquestrants of AGE precursors according to Formula I, Formula I-A, Formula II or Formula II-A are presented in Table 1. It is understood that any or ail of the amines of the structures presented in Table 1 may be in the free amine form or in a protonated form with a pharmaceutically acceptable anion.
Preferred pharmaceutically acceptable anions include but are not limited to chloride, bromide, iodide, carbonate, bicarbonate, sulfate, nitrate, phosphate, acetate, ascorbate, benzoate, citrate, dihydrogen citrate, hydrogen citrate, oxalate, succinate, tartrate, taurocholate, glycocholate, cholate, fiimarate, lactate, malate, tosylate, valerate, mucate, diphosphate and maleate. Most preferred pharmaceutically acceptable anions include chloride, carbonate, and bicarbonate.
Table 1: Amine Based Séquestrants of AGE precursors
| Structure | Description | ||
| ' nh2 hn ' | 5% epichlorohydrin crosslinked low molecular | ||
| /VWV»HN OH | weight poly(vinylamine) | ||
| NH, HN | 10% epichlorohydrin crosslinked low molecular | ||
| 'Λ/νυ'Ν^/-OH | weight poly(vinylamine) | ||
| NH, HN | 10% epichlorohydrin crosslinked high molecular | ||
| H Ί «svw*h 0 H | weight poly(vinylamine) | ||
| ίγίγΊΤ} ' nh2 hn ' | 5% epichlorohydrin crosslinked low molecular | ||
| ΛΛ/νν'ΗΝχ^χ^“0Η | weight poly(vinylamine) | ||
| nh2 x t r 1 HN | y | 10% epichlorohydrin crosslinked | |
| HO^ | Ί NH | poly(methyleneamine) | |
| nh2 X t V J HN. | y | 5% epichlorohydrin crosslinked | |
| HO^ | Ί NH | poly(methyleneamine) | |
| 1 | |||
| 1 | / | J | |
| f / 0 L | /S | Poly {2,3 -diamino {[3 - [(2- | |
| 1 HN | y | ||
| ' I HN | 1 / | methyl-1 -oxo-2-propen-1 yl)amino]propyl] amino }propaneamide- co- | |
| 1 HN | .O | ethylenebismethacrylamide} | |
| ''NHî | (98:2) | ||
| r | |||
| nh2 |
Description
4% epichlorohydrin crosslinked poly{2,3diamino {[3-[(2-methyl-1 oxo-2-propen-lyl)amino]propyl] amino} propaneamide }
Poly {2,3-diamino {[3-[(2methyl-1 -oxo-2-propen-1 yl)amino]ethyl] amino}propaneamide-coethy lenebismethacry lamide} (95:5)
4% epichlorohydrin crosslinked poly(N-allyl-2,3diamino-propane)
Epichlorohydrin cross-linked poly[2-(2,3diaminoethyl)oxazoline)
Poly(3,4-diaminostyrene-codivinyl benzene) (95:5)
| Structure | Description | ||
| C HN | ^R2 X | Poly(N-vinylaniline) | |
| R1' | HN7^ | ^R2 X | Poly(N-vinylpyridin-2amine) |
| R1^ | ch3 I J NH | ^R2 X | Poly(N-methylallylamine) |
| R1 | r NH | ^R2 X | Poly(N-ethylallylamine) |
| .JM' CT'NH 4 ^NH Q A NH HN ^NH HN^ M | Poly(N-(2-acrylamido[y]yl)1,4,8,11tetraazacyclotetradecane-6carboxamide), | ||
| CT^NH * NH n A NH HN ^NH HN^ M | Poly(N-(2methacrylamido [y ]yl)1,4,8,11tetraazacyclotetradecane-6carboxamide) |
| Structure | Description | ||
| R1__ r | ,ΝΗ HN | R2 X | Poly(6-vinyl-l,4,8,l 1tetraazacyclotetradecane) |
| k | NH ΗΙΨ M | ||
| R1-—. [ | ,nhh2n NH Hhf M | -R2 X | Poly{Nl-(2(allylamino)ethyl)-N3-(2aminoethyl)propane-1,3diamine} |
| R1-—. | -R2 | Poly{Nl-(2- | |
| / | | X | (allylamino)ethyl)-N3-(2- | |
| r | „NH HN | (methylamino)ethyl)propane- | |
| L | NH HN^ M | 1,3-diamine} |
In an embodiment of the invention, the séquestrants of AGE precursors are administered in an effective amount to achieve the desired therapeutic effect. The skilled artisan will be able to détermine the effective amount of the séquestrants of AGE precursors depending on the individual and the condition being treated.
In one embodiment of the invention, the séquestrants of AGE precursors and pharmaceutical compositions comprising séquestrants of AGE precursors can be used to bind AGE precursor compounds and dietary dicarbonyl compounds. The séquestrants of AGE precursors of the présent invention may be administered alone or in a pharmaceutical composition comprising a séquestrant of AGE precursors or multiple séquestrants of AGE precursors. Suitable pharmaceutical compositions may comprise a séquestrant of AGE precursors and one or more pharmaceutically acceptable excipients. The form in which the séquestrant of AGE precursors are administered, for example, powder, tablet, capsule, solution, or émulsion, dépends in part on the route by which it is administered. The séquestrants of AGE precursors can be administered, for example, orally. Suitable excipients include, but are not limited to, are inorganic or organic materials such as gelatin, albumin, lactose, starch, stabilizers, melting agents, emulsifying agents, salts and buffers. Suitable pharmaceutically acceptable excipients for topical formulations such as ointments, creams and gels include, but are not limited to, commercially available inert gels or liquids supplemented with albumin, methyl cellulose, or a collagen matrix.
The séquestrants of AGE precursors and pharmaceutical compositions comprising séquestrants of AGE precursors can be administered alone or in combination with one or more additional drugs. Additional drugs administered in combination with the séquestrants of AGE precursors and pharmaceutical compositions comprising séquestrants of AGE precursors of the présent invention include thérapies for the treatment of diabetic nephropathy, chronic kidney disease, atherosclerosis, stroke, cataract, and Alzheimer’s disease. The additional drugs may be administered concomitantly with the séquestrants of AGE precursors or pharmaceutical compositions comprising séquestrants of AGE precursors. The additional drugs may also be administered in sériés with the séquestrants of AGE precursors or pharmaceutical compositions comprising séquestrants of AGE precursors. The pharmaceutical composition comprising séquestrants of AGE precursors may also further comprise a drug used prophylactically and/or therapeutically for the treatment or prévention of diabetic nephropathy, chronic kidney disease, atherosclerosis, stroke, cataract, and Alzheimer’s disease.
In one embodiment of the invention, the number of repeat units and the molecular weight are controlled by the synthesis of the séquestrants of AGE precursors. Methods of preparing preferred séquestrants of AGE precursors of the invention and controlling for the number of repeat units and molecular weights are described in Example 3.
Examples
Example 1: In vitro Studies
Example 1- 1: Dicarbonyl Séquestration
A solution of methylglyoxal (MGO) at a concentration of 50 mg/mL in an aqueous buffer containing 100 mM each of sodium chloride and 2-(Nmorpholino)ethanesulfonic acid (MES) with a pH of 5.8 was prepared. To achieve a pH of 3.0, the solution was titrated with IM hydrochloric acid.
mg of polymeric séquestrant of AGE was added to 50 mL of each MGO solution (pH 5.8 and pH 3.0). The reaction mixture was stirred and an aliquot was taken at appropriate times, ranging from 5 minutes to 24 hours, at minimum an aliquot was taken at 60 minutes. The amount of MGO présent in the test solution, after the timed exposure to the polymer and subséquent filtration to remove the polymer, was determined by gas chromatography after derivatizing the MGO with o-phenylenediamine. The amount of MGO bound to the séquestrants of AGE precurors was determined by subtracting the residual MGO présent in the binding solution from the starting concentration of MGO. The MGO binding properties (mg of MGO/g of séquestrants of AGE precursors) at a pH of 5.8 at 60 minutes are presented in Table 2 below.
k
Table 2: In vitro Methylglyoxal (MGO) Binding Properties of Séquestrants of AGE
Precursors at 60 minutes, pH 5.8
| Séquestrant of AGE | MGO Bound* |
| 5% epichlorohydrin crosslinked low molecular weight poly(vinylamine) | 47 |
| 10% epichlorohydrin crosslinked low molecular weight poly(vinylamine) | 48 |
| 10% epichlorohydrin crosslinked high molecular weight poly(vinylamine) | 48 |
| 5% epichlorohydrin crosslinked high molecular weight poly(vinylamine) | 47 |
| Epichlorohydrin crosslinked Poly[(vinylamine)-co-(vinylguanidine)] | 32 |
| Epichlorohydrin crosslinked Poly[(2- (aminooxy)-7V-(vinyl)-acetamide)-co(vinylamine)] | 43 |
| Poly(3,4-diaminostyrene-co-divinyl benzene)(95:5) | 12 |
| Poly(3,4-diaminostyrene-co-divinyl benzene) (98:2) | 5 |
| Poly {2,3 -diamino {[3 - [(2-methyl-1 -oxo-2propen-1 -yl)amino]propyl] amino }propaneamide- coethylenebismethacrylamide} (98:2) | 43 |
| 5% epichlorohydrin crosslinked poly(methyleneamine) | 49 |
| 10% epichlorohydrin crosslinked poly(methyleneamine) | 33 |
*mg MGO/g séquestrant of AGE precursors
Example 1- 2: Comparative Dicarbonyl Séquestration: Séquestrants of AGE Precursors and Sevelamer Carbonate
Conditions were established to mimic the environment of the stomach and small intestine to conduct comparative in vitro binding studies with 10% epichlorohydrin crosslinked high molecular weight poly(vinylamine) and sevelamer carbonate. A solution of methylglyoxal (MGO) at a concentration of 50 mg/mL in an aqueous buffer containing 100 mM each of sodium chloride and 2-(N-morpholino)ethanesulfonic acid (MES) with a pH of 5.8 was prepared. To achieve a pH of 3.0, the solution was titrated with IM hydrochloric acid. These solutions were intended to mimic the amount of AGE precursors and dietary dicarbonyls présent in the stomach and small intestines after a meal.
mg of test compound (10% epichlorohydrin crosslinked high molecular weight poly(vinylamine) or sevelamer carbonate) was added to 50 mL of each MGO solution at each pH 5.8. The reaction mixture was stirred and an aliquot was taken at appropriate times, ranging from 5 minutes to 24 hours. The amount of MGO présent in the test solution, after the timed exposure to the test compounds and subséquent filtration to remove the test compounds, was determined by gas chromatography after derivatizing the MGO with o-phenylenediamine. The amount of MGO bound to the test compound was determined by subtracting the residual MGO présent in the binding solution from the starting concentration of MGO.
A comparison of the MGO binding properties (mg of MGO/g of the test compounds) at a pH of 5.8 is presented in Erreur ! Source du renvoi introuvable, below. This comparative analysis demonstrated that 10% epichlorohydrin crosslinked high molecular weight poly(vinylamine)is 10-20 times more potent at binding MGO than 25 sevelamer carbonate at pH 5.8.
A comparison of the MGO binding properties (mg of MGO/g of the test compounds) at a pH of 3 is presented in Erreur ! Source du renvoi introuvable, below. This comparative analysis demonstrated that 10% epichlorohydrin crosslinked high molecular weight poly(vinylamine) is 20 times more potent at binding MGO than sevelamer carbonate at pH 3.
K
Example 2: In vivo Studies Example 2-1: Effect of Séquestrants of AGE Precursors in Urémie Rats
Sprague Dawley rats were acclimated to the testing facility for 7 days. The rats were subsequently housed individually in metabolic cages and provided with a diet of rodent meal in food jars. After one week, 1% adenine was added to the diet. Adenine was then adjusted to 0.4% for two weeks to induce kidney impairment. Rats were given adenine free diet for another week. The following week, the rodents were provided diet mixed with 10% epichlorohydrin crosslinked high molecular weight poly(vinylamine).
Blood samples were collected at the end of each week and analyzed for créatinine and carboxymethyl lysine (CML) using an ELISA assay. CML is produced by the reaction between MGO and lysine side chains of proteins. An increase CML value corresponds to AGE formation. The effect of 10% epichlorohydrin crosslinked high molecular weight poly(vinylamine) on the inhibition of the formation of plasma CML is displayed in Erreur ! Source du renvoi introuvable.. 10% epichlorohydrin crosslinked high molecular weight poly(vinylamine) effectively inhibited the formation of plasma CML.
Example 2- 2: Effect of Sevelamer Carbonate in Urémie Rats
Sprague Dawley rats were acclimated to the testing facility for 7 days. The rats were subsequently housed individually in metabolic cages and provided with a diet of rodent meal in food jars. After one week, 1% adenine was added to the diet. Adenine was then adjusted to 0.4% for two weeks to induce kidney impairment. The following week, the rodents were provided diet mixed with sevelamer carbonate.
Blood samples were collected at the end of each week and analyzed for créatinine and carboxymethyl lysine (CML) using an ELISA assay. CML is produced by the reaction between MGO and lysine side chains of proteins. An increase CML value corresponds to AGE formation. The effect of sevelamer carbonate on the inhibition of the formation of plasma CML is displayed in . Sevelamer carbonate had no effect on the formation of plasma CML.
Example 3: Synthesis of Polymeric Séquestrants of AGE
Example 3- 1: Synthesis of 5 mol% Epichlorohydrin Crosslinked Low Molecular Weight Poly(vinylamine).
Example 3-1-1: Synthesis of Low Molecular Weight Poly(vinylamine).
10.0 g of N-vinylformamide, 225 mg of AIBN, and 42 mL of isopropanol were mixed in a 100 mL 3-necked round bottom flask. After purging the reaction mixture for
30 minutes with a slow stream of nitrogen gas, the reaction mixture was stirred at 78°C for 1 hour under nitrogen. After cooling to room température, 50 mL of deionized (DI) water was added to the reaction mixture. The resulting solution was poured into 500 mL of acetone. After stirring for 10 minutes, the solvent was removed. The residue was dissolved in 15 mL of DI water and precipitated into 500 mL of acetone. After filtration, 10 the residue was dried under reduced pressure. The polymer was dissolved in 85 mL of DI water and, to this solution 14.6 g of sodium hydroxide solution (50% aqueous solution) was added. The reaction mixture was stirred at 75°C for 24 hours. The solution was dialyzed using a 3,000 Dalton molecular weight eut off membrane to remove any low molecular weight impurities. The solution was lyophilized, yielding 2.75 g of the product 15 as an off white solid.
Example 3- 1- 2: Crosslinking of Low Molecular Weight Poly(vinylamme) with Epichlorohydrin
1.32 g of low molecular weight poly(vinylamine) (
Example 3-1-1) and 5.28 g of DI water were mixed in a 10 mL glass vial. The reaction mixture was allowed to stir until a homogeneous solution was formed. 125 microliter of epichlorohydrin was added to the solution. The reaction mixture was allowed to stir until a gel formed. The polymer gel was allowed to cure for 48 hours. After breaking into small pièces, the gel particles were suspended in 200 mL of DI water, stirred for 30 minutes, and filtered. The process was repeated twice more; the filtered gel 25 was lyophilized yielding 1.2 g of the product as an off white solid.
Example 3- 2: Synthesis of 10 mol% Epichlorohydrin Crosslinked Low Molecular Weight Poly(vinylamine).
1.32 g of low molecular weight poly(vinylamine) (
Example 3-1- 1) and 5.28 g of DI water were mixed in a 10 mL glass vial. The reaction mixture was allowed to stir until a homogeneous solution was formed. 250 microliter of epichlorohydrin was added to the solution. The reaction mixture was allowed to stir until a gel formed. The polymer gel was allowed to cure for 48 hours. After breaking into small pièces, the gel particles were suspended in 200 mL of DI water, stirred for 30
Ή minutes, and fîltered. The process was repeated twice more; the fîltered gel was lyophilized yielding 1.24 g of the product as an off white solid.
Example 3- 3: Synthesis of 5 mol% Epichlorohydrin Crosslinked High Molecular Weight Poly(vinylamine).
Example 3-3-1: Synthesis of High Molecular Weight Poly(vinylamine).
10.0 g of N-vinylformamide, 130 mg of V50, and 42 mL of deionized water were mixed in a 250 mL 3-necked round bottom flask. After purging the reaction mixture for 30 minutes with a slow stream of nitrogen gas, the reaction mixture was stirred at 60°C for 8 hours under nitrogen. After cooling to room température, the reaction mixture was 10 poured into 500 mL of acetone. After stirring for 10 minutes, the solvent was removed.
The residue was dissolved in 20 mL of DI water and precipitated into 500 mL of acetone. After filtration the residues was under reduced pressure. The resulting polymer was dissolved in 85 mL of DI water, and to this solution 14.6 g of sodium hydroxide solution (50% aqueous solution) was added. The reaction mixture was stirred at 75°C for 24 hours. The solution was dialyzed using a 8,000 Dalton molecular weight eut off membrane to remove any low molecular weight impurities. The solution was lyophilized, yielding 5.45 g of the product as an off white solid.
Example 3- 3- 2: Crosslinking of High Molecular Weight Poly(vinylamine) with Epichlorohydrin.
2 g of the high molecular weight poly(vinylamine) (Example 3-3-1) and 18 mL of DI water were mixed in a 50 mL round bottom flask. The reaction mixture was allowed to stir until a homogeneous solution was formed. 182 microliter of epichlorohydrin was added to the solution. The reaction mixture was allowed to stir until a gel formed. The polymer gel was allowed to cure for 48 hours. After breaking into small pièces, the gel particles were suspended in 400 mL of DI water, stirred for 30 minutes, and fîltered. The process was repeated twice more; the fîltered gel was lyophilized yielding 1.48 g of the product as an off white solid.
Example 3- 4: Synthesis of 10 mol% Epichlorohydrin Crosslinked High Molecular Weight Poly(vinylamine).
2 g of the high molecular weight poly(vinylamine) (Example 3-3-1) and 18 mL of DI water were mixed in a 50 mL round bottom flask. The reaction mixture was allowed to stir until a homogeneous solution was formed. 364 microliter of epichlorohydrin was added to the solution. The reaction mixture was allowed to stir until a gel formed. The polymer gel was allowed to cure for 48 hours. After breaking into small pièces, the gel particles were suspended in 400 mL of DI water, stirred for 30 minutes, and filtered. The process was repeated twice more; the filtered gel was lyophilized yielding 1.8 g of the product as an off white solid.
Example 3- 5: Synthesis of 5 mol% Epichlorohydrin Crosslinked Poly(methyleneamine).
Example 3-5-1: Synthesis of Poly(methyleneamine).
A slurry containing 50 g of 2,2-diethoxyethanamine and 80 g of ice was cooled to -40°C. 76 mL of 5M HCl was added to the slurry in a drop-wise manner. 50 g of potassium isocyanate dissolved in 100 mL of DI water was then added drop-wise to the reaction mixture. The resulting reaction mixture was stirred at reflux température for hours. The reaction mixture was concentrated to a volume of 50 mL under reduced pressure. When cooled to room température, a white precipitate was formed. The precipitate was filtered and dried, yielding 35 g of the product (urea dérivative). The urea dérivative was treated with 1 L 0.05M H2SO4 in a 2.5 L flask. The resulting reaction mixture was stirred for 48 hours. The pH of the slurry was maintained at 7 by the addition of an appropriate amount of aqueous Ba(OH)2 solution. At the end of the reaction, the reaction mixture was filtered. The filtrate was evaporated to dryness, yielding 16 g of
2-hydroxy imidazole as an off white solid.
The resulting 16 g of 2-hydroxy imidazole and 160 mL of acetic anhydride were mixed in a 500 mL 3-necked round bottom flask. The resulting solution was refluxed for hours. The reaction mixture was filtered while hot; the filtrate was concentrated to 50 mL. The solution was placed in a freezer for 30minutes and the resulting slurry was triturated by adding DI water. The slurry was poured into 500 mL of DI water, and the residue was filtered and washed with additional water. The residue was dissolved in methylene chloride and extracted twice with saturated NaHCCh. After drying the organic phase over anhydrous MgSÛ4, the methylene chloride was removed under reduced pressure. The crude product was purified by flash chromatography using an isocratic System of CH2CI2, hexane, and acetone (5:5:1), yielding 14 g of N,N’-diacetyl-230 imidazolone.
1.62 g of N,N’-diacetyl-2-imidazolone and 1.18 mg of l,l'-azobis (cyclohexanecarbonitrile) were mixed in a 10 mL pressure glass vial. The vial was sealed and, through several cycles of freeze-thaw by pump-nitrogen release, the reaction
VL atmosphère made nitrogen. The polymerization was conducted at 130°C for 3 hours. After cooling to room température, the residue was dissolved in 8 mL of DMF and poured into 200 mL of methanol. The suspension was filtered and the supematants were discarded. The précipitation cycle was repeated twice and the resulting residue was dried under reduced pressure, yielding 1.2 g of the polymer.
3.89 g of the resulting polymer, 11 mL of glycerol and 6.5 mL of aqueous 3.54M LiCl solution were mixed in a 25 mL reaction vial. 9.2 g of solid NaOH was added to the mixture. The resulting reaction mixture was refluxed at 150°C for 24 hours. After cooling to room température, the slurry was diluted with water. The reaction mixture was 10 cooled in an ice bath and acidified by slowly adding concentrated HCl. A precipitate was formed and separated by filtration. The resulting solid was subjected to the same process by maintaining the same stoichiometry of NaOH, LiCl and glycerol. After another 24 hours, the above procedure was repeated. The filtrate was dialyzed through a 10 kilodalton membrane filter with several rounds of water exchange. The dialyzed solution 15 was lyophilized yielding 0.94 g of the polymer.
Example 3- 5- 2: Crosslinking of Poly(methyleneamine) with Epichlorohydrin.
200 mg of poly(methyleneamine) (Example 3-5-1) and 0.4 mL of DI water were mixed in a 5 mL glass reaction vial. The reaction mixture was stirred until a homogeneous solution was obtained. 3 drops of 50% sodium hydroxide solution were 20 added to the solution, followed by 24 microliter of epichlorohydrin. The reaction mixture was stirred at room température for 14 hours and then stirred at 60°C for 8 hours. The polymer gel was broken into small pièces and dialyzed through a 10 kilodalton dialysis membrane with multiple water exchanges. The dialyzed polymer gel was lyophilized yielding 170 mg of the polymer.
Example 3- 6: Synthesis of 2 mol% Epichlorohydrin Crosslinked Poly(methyleneamine).
300 mg of poly(methyleneamine) (Example 3-5-1) and 0.5 mL of DI water were mixed in a 5 mL glass reaction vial. The reaction mixture was stirred until a clear solution was obtained. 4 drops of 50% sodium hydroxide solution were added to the 30 solution, followed 18 microliter of epichlorohydrin. The reaction mixture was stirred at room température for 14 hours and at 60°C for 8 hours. The polymer gel was broken into small pièces and dialyzed through a 10 k Da dialysis membrane with multiple water exchanges. The dialyzed polymer gel was lyophilized yielding 250 mg of the polymer.
Example 3- 7: Synthesis of poly{2,3-diammo{[3-[(2-methyl-l-oxo-2-propen- l-yl)amino]propyl]amino}propaneamide- co-ethylene bis-methacrylamide} (98:2). Example 3-7-1: Synthesis of 23~di(N-boc)aminopropanoic acid.
5.23 g of 2,3-Diaminopropanoic acid hydrochloride was dispersed in 84 mL of dioxane:water (1:1) mixture. 26 mL oftriethylamine was added to this suspension and resulted in a clear solution. 19.9 g of Boc anhydride and the reaction mixture was allowed to stir at room température for 16 hours. The volume of the reaction mixture was reduced to ~ 20 mL under reduced pressure. 20 mL of 4M sodium hydroxide was added to this concentrated reaction mixture. Subsequently DI water was added in a drop-wise manner until the reaction mixture became homogenous. The aqueous phase was extracted with diethyl ether (2 x 100 mL). The aqueous phase was collected and 100 mL of ethyl acetate was added to it. The two phase System was stirred rapidly in a 500 mL round bottom flask. While stirring, 1.2M HCl was slowly added to the reaction mixture until the pH of the aqueous phase was ~1.5. The phases were separated and the aqueous phase was extracted with ethyl acetate (2 x 100 mL). The combined organic phase was washed with 20 mL of brine and dried over anhydrous MgSÛ4. After filtration, the reaction mixture was evaporated to dryness. The residue was treated with warm diethyl ether and filtered. The solvent was removed under reduced pressure. The ether treatment was repeated twice, yielding 10.8g of the product as a white solid.
Example 3-7-2: Synthesis of NHS ester of 2,3-Di(N-boc)aminopropanoic acid.
2.0 g of 2,3-Di(N-boc)aminopropanoic acid (Example 3- 7- 1), 756 mg of Nhydroxysuccinimide, and 15mL of dichloromethane were combined in a 250 mL round bottom flask. The resulting solution was cooled to 0°C in an ice bath and 1.56g (7.56 mmol) DCC was added. After stirring at 0°C for 15 minutes, the reaction mixture was slowly allowed to warm to room température, and then stirred at room température for an additional 3 hours. The reaction mixture was again cooled to 0°C and the precipitate that formed was filtered off. The residue was rinsed with cold dichloromethane and the filtrate was diluted with 10 mL of dichloromethane. The resulting solution was extracted with DI water (2 x 25 mL) followed by saturated NaHCCh solution (2 x 25 mL). The organic phase collected and then dried over NaîSCU. After filtration, the solvent was removed under reduced pressure. The residue was dissolved in 15mL diethyl ether and kept at -20°C for 16 hours. The solid precipitate that formed was filtered and rinsed with mL of cold ether. After drying under reduced pressure, 2.44g of the desired product was obtained as a white powder.
Example 3- 7- 3: Synthesis of 2,3-diamino{[3-[(2-methyl-l-oxo-2-propen-lyl)amino]propyl]amino}propaneamide.
1.1g of NHS ester of 2,3-di(N-boc)aminopropanoic acid (Example 3- 7- 2), 15 mL of acetonitrile and 1.4 mL of triethyl amine were combined in a 100 mL round bottom flask. 0.98 g of N-(3-aminopropyl)-methacrylamide hydrochloride was slowly added to the solution. The resulting reaction mixture was stirred at room température for 18 hours. After removing the solvent under reduced pressure, the residue was dissolved in minimum amount of dichloromethane and was purified by silica gel flash chromatography using a gradient of ethyl acetate/hexane. After combining appropriate fractions the solvent was removed under reduced pressure yielding 0.75 g of the desired product as an off white solid.
Example 3- 7- 4: Synthesis of poly{2,3-diamino{[3-[(2-methyl-l-oxo-2-propen-ly 1)aminojpropyl] amino} propaneamide- co-ethylene bis-methacrylamide} (98:2).
0.95 g of 2,3-Di(N-Boc)amino-[[3-[(2-methyl-l-oxo-2-propen-lyl)amino]propyl]amino]-propaneamide (Example 3- 7- 3), 9.5 mg of V50, 8.7 mg of ethylene bismethacrylamide, and 1.8 mL of éthanol were added to a 10 mL glass vial. After bubbling with a slow stream of nitrogen for 30 minutes, the reaction mixture was kept at 70°C for 30 hours. After cooling to room température, the reaction mixture was treated with 5mL of 3 M methanolic HCl and was stirred at room température for 16 hours; the reaction mixture was then heated to 50°C and stirred for an additional 3 hours. The methanol was removed and the polymer was dialyzed through a 10 kDa dialysis membrane for 48 hours. The resulting solution was lyophilized, yielding 0.54 g of the polymer.
Example 3- 8: Synthesis of 4 mol% epichlorohydrin crosslinked Poly {2,3diamino{[3-[(2-methyl-l-oxo-2-propen-l-yl)amino]propyl] aminojpropaneamide}.
1.0 g of 2,3-Di(N-Boc)amino-[[3-[(2-methyl-l-oxo-2-propen-lyl)amino]propyl]amino]-propaneamide (Example 3- 7- 3), 10.0 mg of V50, and 2 mL of éthanol were added to a 10 mL glass vial. After bubbling with a slow stream of nitrogen for 30 minutes, the reaction mixture was kept at 70°C for 24 hours. After cooling to room température, the reaction mixture was treated with 5 mL of 3 M methanolic HCl and was stirred at room température for 16 hours; the reaction mixture was then heated to 50°C and stirred for an additional 3 hours. The methanol was removed and the residue was dissolved in 5 mL of 1.2 M HCl. The resulting solution was dialyzed against DI water using a 10 k Da dialysis membrane for 48 hours. The dialyzed solution was lyophilized, yielding 0.6 g of the polymer.
0.1 g of the above polymer and 0.25 mL of DI water were added in a 5 mL reaction vial. After a clear solution formed, 22 mg of KOH was added, followed by 1 microliter of epichlorohydrin. The reaction mixture was allowed to stir at room température for 18 hours, during which time the polymer gel was formed. The gel was broken into small pièces and was dialyzed against DI water using a 10 kDa dialysis membrane for 48 hours. Lyophilization of the dialyzed gel offered 91 mg of the desired polymer as an off white solid.
Example 3- 9: Synthesis of poly{23-diamino{[3-[(2-methyl-l-oxo-2-propen-lyl)amino] ethyl]amino}propaneamide- co-ethylene bis-methacryiamide} (95:5) Example 3-9-1: Synthesis of N-(2-aminoethyl)methacrylamide.
3.2 g of N-Boc-ethylenediamine, 3 mL of triethylamine, and 20mL of acetonitrile were combined in a 250 mL three necked round bottom flask. The resulting solution was treated with 5.5 g of N-hydroxysuccinimide méthacrylate dissolved in 20mL of acetonitrile followed by another 3 mL of triethylamine. The reaction mixture was stirred at room température for 16 hours. The solvent was removed under reduced pressure and the residue was dissolved in tert-butylmethyl ether. The residual mass was dissolved in a two phase System of tert-butylmethyl ether and saturated Na2CO3. The aqueous phase was extracted with 20 mL of tert-butylmethyl ether. The combined organic phase was extracted with 10% citric acid followed by saturated NaHCO3. The organic phase was collected and dried over MgSCh. After filtration, the solvent was removed under reduced pressure. The residue was placed in a 50 mL round bottomed flask and treated with 10 mL of 4M HCl in 1,4-dioxane. The reaction mixture was stirred at room température for 18 hours. The suspension was centrifuged. After removing the supematant, the residue was dissolved in lOmL of DI water and lyophilized, yielding 1.2 g of the product as a white solid.
Example 3-9-2: Synthesis of 2,3-diamino{[3-[(2-methyl-l-oxo-2-propen-lyl)amino] ethyl] amino} propaneamide.
1.55 g of 2,3-Di(N-boc) aminopropanoic acid (Example 3- 7-1), 15mL of tetrahydrofuran (THF) and 1.1 mL of triethylamine were combined in a 50 mL round bottom flask. The solution was stirred at 0°C and 770 microliter of isobutylchloroformate was added to the stirred solution in a drop-wise manner. The reaction mixture was allowed to warm to room température slowly and was stirred for one hour at room température. After adding 0.85 mL of triethylamine, a solution containing 1 g of N5 [2-aminoethyl]methylacrylamide hydrochloride in 3mL of N,N-dimethylformamide (DMF) was slowly added to the reaction mixture. The resulting reaction mixture was stirred at room température for 15 hours. The reaction mixture was filtered and the residue was washed with cold DI water and dried under reduced pressure. The dried solid was dissolved in 20 mL methanol; to this solution 6 mL of concentrated HCl was added in a drop-wise manner. After stirring the reaction mixture for 48 hours at room température, the solvent was removed under reduced pressure. The residue was dissolved in 15 mL of DI water and lyophilized, yielding 1.1 g of the monomer as a white solid. Example 3- 9- 3: Synthesis of poly{2,3-dianiino{[3-[(2-methyI-l-oxo-2-propen-lyl)amino] ethyl] aminojpropaneamide- co-ethylene bis-methacrylamide} (95:5).
0.7 g of 2,3-diamino-[[2-[(2-methyl-l-oxo-2-propen-l-yl)amino]ethyl]amino]propaneamide (Example 3- 9-1), 7.0 mg of V50,17.0 mg of ethylene bismethacrylamide, and 1.3 mL of DI water were combined in a 10 mL glass vial. After bubbling with a slow stream of nitrogen for 20 minutes, the reaction mixture was stirred at 70°C for 18 hours. The polymer gel that formed was treated with 20 mL of éthanol and stirred for 24 hours. The resulting gel was broken into small pièces and the suspension was centrifuged. The supematant was decanted and the residue was washed with éthanol (2 x 20 mL). After removing éthanol, the residue was treated with 15 mL of 1.2M HCl and dialyzed against water using 12 kDa dialysis membrane for 48 hours. The dialyzed slurry was lyophilized, yielding 0.4 g of the polymer as an off white solid.
Example 3-10: Synthesis of epichlorohydrin crosslinked Poly(N-allyl-2,3-diaminopropaneamide).
Example 3-10-1: Synthesis of Poly(N-allyl-2,3-diaminopropaneamide).
0.5 mL N-methylmorpholine (NMP) followed by 2mL of methanol was added to a solution of 95 mg of poly(allylamine) dissolved in 5mL of methanol. While stirring, 2.0 g of NHS ester of 2,3-di(N-boc)aminopropanoic acid (Example 3- 7- 1)) was added to the solution. The reaction mixture was stirred at room température until a clear solution formed. Subsequently it was stirred at 50°C for six days. After cooling to room température, 3 mL of concentrated HCl was added, followed by 2 mL of water. The
VL· resulting reaction mixture was stirred at 50°C for 15 hours. After cooling to room température, the reaction mixture was dialyzed through a 5 kDa dialysis membrane for 48 hours. The dialyzed polymer solution was lyophilized, yielding 0.16 g of the polymer. Example 3-10- 2: Epichlorohydrin crosslinking of poly(N-ally 1-2,3diaminopropaneamide).
153 mg ofpoly(2,3-diamino-[allylamino]-propaneamide) (Example 3-10-1) and 0.4 mL of DI water were combined in a 5 mL glass vial. When a clear solution formed, 150 mg sodium carbonate was added. While stirring, 2 pL of epichlorohydrin was added to the polymer solution. The reaction mixture was stirred at room température for 2 hours, followed by stirring at 60°C for 15 hours. The polymer gel that formed was dialyzed against DI water using 10 kDa dialysis membrane for 48 hours. The dialyzed polymer was lyophilized, yielding 112 mg of the product.
Example 3-11: Synthesis of Poly[2-(2,3-diaminoethyl)oxazoline). Example 3-11-1: Synthesis of2-[2,3-di(N-boc)aminoethyl]oxazoline.
1.1g of 2,3-di(N-boc)aminopropanoic acid (Example 3- 7-1), 0.88 g of 2bromoethyl amine hydrobromide, 0.5 mL of NMM, and 32 mL of methanol were added to a 250 mL round bottom flask. 1.2 g of 4-(4,6-dimethoxy-l ,3,5-triazin-2-yl)-4methylmorpholinium chloride was added to the solution. The resulting reaction mixture was stirred at room température for one hour. After adding 0.85 g of KOH dissolved in 15 mL of methanol, the reaction mixture was stirred at reflux température for 3.5 hours. The solvent was removed and the residue was dissolved in 100 mL of tert-butylmethyl ether. The ether solution was extracted with DI water (2 x 100 mL) and the organic phase was dried over MgSCU After removing the solvent, the residue was purified by silica gel flash chromatography using a gradient of ethyl acetate and hexane as the eluting solvent System. Removal of the solvent yielded 0.8 g of the desired product.
Example 3- 11- 2: Polymerization of 2-|2,3-di(N-boc)aminoethyl]oxazoline.
0.58 g of 2-[2,3-di(N-boc)aminoethyl]oxazoline (Example 3-11-1) and 0. 46 mL of anhydrous acetonitrile were added to an oven-dried 5 mL glass vial. 5.5 mg of 4,5dihydro-2,3-dimethyloxazoliumtrifluoromethanesulfonate as a 4.3% solution in acetonitrile was added to the solution. The resulting reaction mixture was stirred at 80°C for 5 days. After cooling to room température, 22 microliter of piperidine was added and the reaction mixture was stirred at room température for 48 hours. The reaction mixture was subsequently evaporated to dryness and the residue was dissolved in 3mL of dichloromethane. 3 mL of trifluoroacetic acid was added to the resulting solution and then stirred at room température for 16 hours. After removing the solvent, the residue was treated with 15 mL of 1.2M HCl. After a clear solution was formed, 1 mL of concentrated HCl was added and the resulting reaction mixture was stirred at 50°C for 18 hours. After cooling to room température, the solution was filtered through a 0.2 pm filter and the filtrate was lyophilized, yielding 0.4 g of poly[2-(2,3-diaminoethyl)oxazoline).
Example 3-12: Synthesis of poly(3,4-diaminostyrene-co-divinyl benzene) (98:2). Example 3-12- 1: Synthesis of 4-vinyl-2-nitroaniline.
5.76 g of 2,4,6,8-tetramethyltetravinylcyclotetrasiloxane, 0.25 g of palladium dibromide and 0.55 g of (2-biphenyl)di-tert-butylphosphine were added to a 250 mL, 3neck round bottom flask. While maintaining a nitrogen atmosphère, 40 mL of IM tetrabutylammonium fluoride in THF was added to the flask, followed by 4.0 g of 4bromo-2-nitroaniline dissolved in 10 mL of THF. The reaction was stirred at 50°C for 16 hours under nitrogen atmosphère. After cooling to room température, 60 mL of diethyl ether was added and the reaction mixture was stirred at room température for 30 minutes. The reaction mixture was extracted with DI water (2 x 100 mL). The organic phase was allowed to pass through a plug of silica. The filtrate was evaporated to dryness and the residue was subjected to silica gel flash chromatography using a gradient of dichloromethane and hexane as the eluting solvent. The desired fractions were collected and evaporated to dryness, yielding 2.19g of 4-vinyl-2-nitroaniline.
Example 3- 12- 2: Synthesis of 3,4-diaminostyrene.
3.45 g of 4-vinyl-2-nitroaniline (Example 3- 12-1), 20.2 g of sodium sulfide nonahydrate, 30 mL of éthanol, and 30 mL of DI water were combined in a 250 mL round bottom flask. The reaction mixture was refluxed for 18 hours. After removing éthanol under reduced pressure, the aqueous phase was extracted with ethyl acetate (3 x 100 mL). The combined organic phase was washed with brine followed by drying over anhydrous MgSCU. After filtration, 0.5g of activated charcoal was added to the solution and the slurry was heated to reflux for 30 minutes. The slurry was filtered through a plug of celite. The filtrate was evaporated to dryness and the residue was purified by flash chromatography by using amine modified silica gel as the stationary phase and a gradient of ethyl acetate/hexane as the mobile phase. The desired fractions were combined and evaporated to dryness. The residue was recrystallized from a mixture of ethyl acetate/hexane, yielding 1.8 g of the product.
Example 3-12- 3: Synthesis of t-Boc protected 3,4-diaminostyrene.
1.75 g of 3,4-diaminostyrene (Example 3-12- 2) and 20mL of acetone were combined in a 100 mL 3-neck round bottom flask. To this solution, 8.54 g of t-Boc anhydride was added, followed by the addition of 20 mL of IM sodium hydroxide. The reaction mixture was allowed to stir at room température for 84 hours. After filtration, the acetone was removed under reduced pressure. The residue was treated with 25 mL of ethyl acetate and 25 mL of DI water. After shaking, the phases were separated. The aqueous phase was extracted with 25 mL of ethyl acetate. The combined organic phase was washed with brine and dried over anhydrous MgSO4. After filtration, the solvent was evaporated. The residue was treated with 50 mL of hexane, stirred for 30 minutes and evaporated to dryness. The residue was subsequently dissolved in 125 mL refluxing hexane. The solution was filtered and the filtrate was kept at -20°C for 18 hours. The solid that formed was filtered and washed with 5 mL of cold hexane. The residue was dried under reduced pressure yielding 3.55g of the desired product.
Example 3-12- 4: Synthesis of divinyl benzene crosslinked 3,4-diaminostyrene polymer.
Ail manipulations were carried out by keeping exposure to light at the minimum.
1.0 g of t-Boc protected 3,4-diaminostyrene (Example 3-12- 3), 8 mg of
1,4-divinylbenzene, 3 mL of toluene, and 10 mg of AIBN were combined in a 10 mL glass vial. After flushing the solution with a slow stream of nitrogen for 15 minutes, the reaction mixture was kept at 80°C for 18 hours, yielding a swollen gel. The gel was treated with 6 mL of methanol followed by 6 mL of 3 M methanolic HCl. The resulting reaction mixture was stirred at room température for 18 hours, and then stirred at 45°C for 3 hours. After removing the solvent, the residue was treated with 10 mL of 1.2 M HCl and dialyzed against DI water using a 12 kDa dialysis membrane for 48 hours. The gel was subsequently lyophilized, yielding 0.4g of the desired product.
Example 3- 13: Synthesis of glutaraldehyde crosslinked poly(3,4-diaminostyrene).
Example 3-13-1: Synthesis of soluble poly(3,4-diaminostyrene).
Ail manipulations were performed with minimum exposure to light. 1.0 g of tBoc protected 3,4-diaminostyrene (Example 3-12- 3), 3 mL of toluene and 10 mg of AIBN were combined in a 10 mL glass vial. The resulting solution was bubbled with a slow stream of nitrogen for 15 minutes. The reaction vial was sealed and heated at 80°C for 18 hours. After removal of toluene, the residue was dissolved in 6 mL methanol, followed by the addition of 6 mL of 3 M methanolic HCl. The reaction mixture was stirred at room température for 18 hours, and then stirred at 45°C for 3 hours. The solvent was removed and the residue was dissolved in 10 mL of 1.2 M HCl. The resulting solution was dialyzed against DI water using a 12 kDa dialysis membrane for 48 hours. The dialyzed solution was lyophilized, yielding 0.65 g of the polymer.
Example 3-13- 2: Synthesis of 5 mol% glutaraldehyde crosslinked poly(3,4diaminostyrene).
0.63 g of poly-3,4-diaminostyrene (Example 3-13-1) dissolved in 1.5 mL of DI water was added to 30.4 mg of 50 wt.% aqueous glutaraldehyde solution. While stirring, 0.2 g of sodium cyanoborohydride was added to this solution. The resulting reaction mixture was stirred at 45°C for 48 hours. 5 mL of 1.2M HCl was added to the reaction mixture and stirred for an additional 24 hours. The reaction mixture was then dialyzed against DI water through a 10 kDa dialysis membrane for 48 hours. The dialyzed gel was lyophilized, yielding 0.3 g of the polymer gel.
Example 3-14: Synthesis of ethylene bis-methacrylamide crosslinked poly(arginine methacrylamide) (95:5).
Example 3- 14- 1: Synthesis of arginine methacrylamide monomer.
1.6 g of potassium hydrogencarbonate, 12 mL of DI water and 1 g of arginine were combined in a 100 mL round bottom flask. 5 mL of acetone was added to this solution. The reaction mixture was cooled to 0°C. To this stirred cold solution, 0.6 g of methacryloyl chloride dissolved in 3 mL of dioxane was added in a drop-wise manner over a period of 10 minutes. The reaction mixture was stirred at 0°C for 1 hour, and then stirred for 2 hours at room température. The pH of the reaction mixture was brought to
1.0 with concentrated HCl. After adding 20 mL of saturated sodium chloride solution, the reaction mixture was washed with ethyl acetate (3 x 25 mL). The ethyl acetate layer was subsequently discarded. The aqueous layer was extracted with a 1:1 (v/v) mixture of ethyl acetate: isopropanol (3 x 50 mL). The combined organic phase was concentrated under reduced pressure. Additional isopropanol was added and the solution was concentrated again. The deposited sodium chloride was removed by filtration, and the filtrate was evaporated to dryness, yielding 0.8 g of desired product as viscous colorless oil.
Example 3-14- 2: Synthesis of poly(arginine methacrylamide-co-ethylene bismethacrylamide).
0.8 g of arginine methacrylamide hydrogen chloride (Example 3-14-1), 26 mg of ethylene bis-methacrylamide, and 2.2 mL of DI water were combined in a 10 mL glass vial. To this solution 7.3 mg of V50 was added. After flushing with a slow stream of nitrogen for 30 minutes, the vial was sealed and stirred at 65 °C for 16 hours. The polymer gel that formed was dispersed in 20 mL of 1 M HCl and centrifuged. The supematant was removed and the process was repeated four more times. The residue was lyophilized, yielding 0.4 g of the polymer gel.
Example 3- 15: Synthesis of ethylene bis-methacrylamide crosslinked poly(agmatine methacrylamide).
Example 3-15-1: Synthesis of agmatine methacrylamide monomer.
4.14 g of potassium carbonate, 10 mL of DI water, and 2.28 g of agmatine sulfate and 5 mL of acetone were combined in a 100 mL round bottom flask. 2.1 g methacryloyl 15 chloride dissolved in 2 mL of dioxane was added in a drop-wise over a period of 10 minutes while stirring at 0°C. The reaction mixture was stirred for additional 2 hours. Subsequently the reaction mixture was extracted with ethyl acetate (3 x 20 mL). The combined organic layer was dried over anhydrous MgSCL. It was filtered and the filtrate was concentrated under reduced pressure. The residue was redissolved in 10 mL of THF.
To this solution 1 mL of 4M HCl in dioxane was added. The precipitate that formed was isolated and dried under reduced pressure, yielding 1.2 g of the desired product.
Example 3-15-2: Synthesis of poly(agmatine methacrylamide-co-ethylene bismethacrylamide) (90:10).
0.92 g of agmatine methacrylamide HCl (Example 3- 15-1), 77.1 mg of ethylene bis-methacrylamide, and 3 mL of DI water were combined in a 10 mL glass vial. After a clear solution was obtained, 9.22 mg of V50 was added. The resulting reaction mixture was bubbled with a slow stream of nitrogen for 30 minutes. The vial was sealed and stirred at 65°C for 18 hours. The gel that formed was treated with 20 mL of 1 M HCl. After breaking the gel into small pièces, the resulting suspension was centrifuged. The supematant was removed and the residue was collected. The 1 M HCl treatment and centrifugation process was repeated three times. The filtered residue was lyophilized, yielding 0.5 g of the desired polymer.
Example 3-15-3: Synthesis of poly(agmatine methacrylamide-co-ethylene bismethacrylamide) (95:5).
0.92 g of agmatine methacrylamide HCl (Example 3-15-1), 38.4 mg of ethylene bis-methacrylamide, and 3 mL of DI water were combined in a 10 mL glass vial. After a clear solution was obtained, 9.22 mg of V50 was added to this solution. The resulting reaction mixture was bubbled with a slow stream of nitrogen for 30 minutes. The vial was sealed and stirred at 65°C for 18 hours. The gel that formed was treated with 20 mL of 1 M HCl. After breaking the gel into small pièces, the resulting suspension was centrifuged. The supematant was removed and the residue was collected. The 1 M HCl treatment and centrifugation process was repeated three times. The filtered residue was lyophilized, yielding 0.45 g of the desired polymer.
Exemple 3-16: Synthesis of glyoxal crosslinked poly(0-vinyl hydroxylamine-covinyl alcohol).
Example 3-16-1: Synthesis of poly(0-vinyl hydroxylamine-co-vinyl alcohol).
2.0 g of poly(vinyl alcohol) (molecular weight of 10 kDa) and 20 mL of anhydrous NMP were combined in a 100 mL round bottom flask. The reaction mixture was heated to 60°C. The resulting solution was subjected to five cycles of azeotropic distillation using anhydrous toluene. After removing the solvent under reduced pressure, the residue was dried under vacuum. Subsequently, the dried polymer was transferred into a 500 mL 3-necked round bottom flask under nitrogen atmosphère to 100 mL of anhydrous NMP was added. To this polymer solution 47.3 g of triphenylphosphine and
29.5 g of N-hydroxyphthalimide was added. The reaction mixture was heated to 45°C to obtain clear solution. After cooling to -3°C using a salt/ice bath, 1.6 g of activated molecular sieves (4Â) was added to the reaction mixture. To this stirred reaction mixture
35.2 mL of diisopropyl azodicarboxylate was added in a drop-wise manner over a period of 30 minutes. The resulting reaction mixture was stirred at -3°C for 1 hour, slowly warmed to room température, and then stirred at room température for 48 hours. After removing the molecular sieves by filtration, the solution was precipitated into 2 L of DI water. The solvent was removed and the residue was dissolved in minimal amount of methanol:ethanol mixture (1:1, v/v). The resulting solution was precipitated into 2 L of diethyl ether. After removing the solvent, the residue was dissolved in minimal amount of chloroform and precipitated from 2 L of diethyl ether. After removing the solvent, the precipitate was dried under reduced pressure, yielding 3.8 g of the product.
The dried residue and 40 mL of dioxane: methanol (2:1) were combined in a 250 mL 3-necked round bottom flask. The mixture was stirred until a clear solution was obtained. To this polymer solution was added 8.9 mL of hydrazine monohydrate and the reaction mixture was stirred at reflux température for 3 hours. After removing the solvent under reduced pressure, the residue was dispersed in 100 mL of deionized water. The pH of the dispersion was adjusted to 2.0 with concentrated HCl and the resulting reaction mixture was refluxed for 15 minutes. To this reaction mixture 100 mL of DI water was added and the resulting dispersion was refluxed for 45 minutes. After cooling to room température, the reaction mixture was filtered and the filtrate was dialyzed against DI water using a 2 kDa dialysis membrane for 72 hours. The dialyzed solution was lyophilized yielding 0.84 g of the desired product as an off white solid.
Example 3-16-2: Glyoxal crosslinking of poly(O-vinyI hydroxylamine-co-vinyl alcohol).
0.31 g of Poly(O-vinyl hydroxylamine-co-vinyl alcohol) (Example 3-16-1) and
1.8 mL of DI water were combined in a 10 mL glass vial. After a clear solution was obtained, 8 microliter of 40% aqueous glyoxal was added. The reaction mixture was stirred for 5 minutes to form a soft gel. The gel particles were broken and transferred into a 100 mL round bottom flask with 20 mL of DI water. 63 mg of sodium cyanoborohydride was added to the suspension and the resulting reaction mixture was stirred at 45°C for 48 hours. After cooling to room température, the reaction mixture was filtered. The residue was dispersed in 10 mL of DI water and the pH of the dispersion was brought to 2.0 by slow addition of 1 M HCl. After stirring for 20 minute, the pH was raised to 8.0 by slow addition of 1 M sodium hydroxide. After filtration, the residue was dispersed in 30 mL of DI water and stirred for 30 minutes. The polymer was filtered and this process of water treatment was repeated twice. The residue was finally dialyzed against DI water for 72 hours using an 8 kDa dialysis membrane. The dialyzed polymer gel was lyophilized, yielding 0.12 g of the polymer.
Example 3-17: Synthesis of epichlorohydrin crosslinked poly{2-(aminooxy)-Nvinylacetamide-co-vinylamine).
0.15 g of 10 mol% epichlorohydrin crosslinked high molecular weight poly(vinylamine) (Example 3- 4) and 15 mL of deionized water were combined in a 100 mL 3-necked round bottom flask. 1.71 g of N-hydroxysuccinimde ester of t-Boc protected aminooxy glycine dissolved in 10.0 mL of dimethylsulfoxide was added to the suspension. The resulting reaction mixture was stirred at 60°C for 2 hours. 1.65 g of Nhydroxysuccinimde ester of t-Boc protected aminooxy glycine in 2 mL of dimethylsulfoxide was subsequently added and the reaction mixture was stirred at 60°C for additional 6 hours. The pH of the reaction mixture was maintained at 10.0 with the occasional addition of 1 M NaOH throughout the process. After filtration, the gel particles were suspended in 25 mL of methanol and stirred for 30 minutes. The polymer was filtered and the filtered gel was subjected to the methanol treatment process two more times. Subsequently, the gel was dispersed in 25 mL of DI water, stirred for 30 minutes and filtered. After repeating the water treatment process two more times, the filtered polymer was lyophilized to dryness, yielding 176 mg of the polymer gel.
The polymer gel was combined with 10 mL DI water in a 100 mL 3-necked round bottom flask. While stimng, 4 mL of 1 M HCl was added and the reaction mixture was stirred at 40°C for 2 hours. 2 mL of 1 M HCl was subsequently added and the reaction mixture was stirred at 40°C for additional 16 hours. After cooling to room température, the pH of the suspension was adjusted to 5.8 by the addition of 1 M NaOH. The polymer gel was filtered and the filtered gel was suspended in 25 mL of DI water. The suspension was stirred for 30 minutes and filtered. After repeating the water treatment process three times, the filtered gel was lyophilized, yielding 125 mg of the desired product.
Example 3- 18: Synthesis of Epichlorohydrin Crosslinked Poly(vinylamine-covinylguanidine).
Example 3- 18- 1: Synthesis of Epichlorohydrin Crosslinked Poly(vinylamine).
In a 50 mL beaker were taken 2 g of poly(vinylamine) and 18.00 mL of deionized water. The reaction mixture was stirred at room température until a clear solution was obtained. To this solution was added 0.36 mL of epichlorohydrin. The resulting reaction mixture was stirred until a gel was formed (after approximately 22 minutes). The stirring was discontinued and the gel was allowed to stand at room température for 48 hours. Subsequently the gel was broken into smaller pièces, suspended in 400 mL of deionized water, stirred for 30 minutes, and filtered. After repeating this washing process two more times, the filtered gel was lyophilized yielding 2.2 g of the polymer as an off white solid.
Example 3-18-2: Synthesis of Epichlorohydrin Crosslinked Poly(vinylamine-covinylguanidine)
U
In a 250 mL three-necked round bottom flask were taken 0.5 g of epichlorohydrin crosslinked poly(vinylamine) (Example 3- 18-1) and 50 mL of deionized water. The pH of the suspension was adjusted to 10.55 by adding appropriate amount of 50% (w/w) aqueous NaOH and stirred under nitrogen. In a 100 mL round bottomed flask were taken
6.97 g of pyrazole carboxamidine hydrochloride and 25 mL of deionized water. The pH of the solution was adjusted to 6.85 by adding appropriate amount of IM NaOH. The resulting solution was added to the polymer suspension and the pH was adjusted to 10.60 by adding appropriate amount of 50% aqueous NaOH. The resulting reaction mixture was stirred under nitrogen at 60°C for 40 hours. After cooling to room température, the suspension was fîltered, dispersed in 100 mL of deionized water, stirred for 30 minutes, and fîltered. After repeating washing process four more times, the fîltered gel was lyophilized yielding 0.52 g of the polymer as an off white solid.
Example 3-1: Synthesis of 5 mol% Epichlorohydrin Crosslinked Low Molecular Weight Poly(vinylamine).
Example 3- 19: Synthesis of poly(3,4-diaminostyrene-co-divinyl benzene) (95:5). Example 3-19-1: Synthesis of divinyl benzene crosslinked 3,4-diaminostyrene polymer.
Ail manipulations were carried out by keeping exposure to light at the minimum. 1.0 g of t-Boc protected 3,4-diaminostyrene (Example 3- 12- 3), 19.5 mg of 1,4-divinylbenzene, 2 g of toluene, and 10 mg of AIBN were combined in a 10 mL glass vial. After flushing the solution with a slow stream of nitrogen for 15 minutes, the reaction mixture was kept at 80°C for 18 hours, yielding a swollen gel. The gel was treated with 6 mL of methanol followed by 6 mL of 3 M methanolic HCl. The resulting reaction mixture was stirred at room température for 18 hours, and then stirred at 45°C for 3 hours. After removing the solvent, the residue was treated with 10 mL of 1.2 M HCl and dialyzed against DI water using a 12 kDa dialysis membrane for 48 hours. The gel was subsequently lyophilized, yielding 0.4g of the desired product.
8 AOUT 2015
CablnJtl :£azena&sarl
Prowftté Indujtfiellô
BP: 5Q0Taounjté4Cameroun)
W: (23#<22 21B2 89 /FBXÛ237) 222 20Ç4-hr
Claims (63)
- Claims1. A pharmaceutical composition comprising a compound, wherein the compound comprises the structure of Formula I:(I) wherein:n is 0,1, or 2;o is 0, 1, or 2;x is an integer from 2 to 25,000;R1 and R2 are each independently a pharmaceutically acceptable end group, a polymer, or -Rx-polymer, wherein Rx is selected from (Ci-Cio)alkyl, (C2-C9)heteroalkyl, (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (C6-Ci4)aryl, (C2-C9)heteroaryl, (Ci-Cio)alkylamine, -0(0)C-(Ci-Cio)alkyl, (Ci-Cio)alkyl-COOH, (C3-C!0)cycloalkyI-COOH, -(O)CH3, -OH, amide;R3 and R4 are each independently H, a polymer, or -Rx-polymer, wherein Rx is selected from (Ci-Cio)alkyl, (C2-C9)heteroalkyl, (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (Cô-Ci4)aryl, (C2-C9)heteroaryl, (Ci-Cio)alkylamine, -0(0)C-(Ci-Cio)aIkyl, (Ci-Cio)alkyl-COOH, (C3-Cio)cycloalkyl-COOH, -(O)CH3, -OH, amide, or if n is 0 R4 is absent, and if o is 0 R3 is absent; andR5 and R6 are each independently H, (Ci-Cio)alkyl, (C2-C9)heteroalkyl, (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (C6-Ci4)aryl, (C2-C9)heteroaryl, (CiCio)alkylamine, -0(0)C-(Ci-Cio)alkyl, (Ci-Cio)alkyl-COOH, (C3-Cio)cycloalkylCOOH, -(O)CH3, -OH, -NH2, -NH(Ci-Cio)alkyl, -N[(Ci-Cio)alkyl]2 orKR5 and R6 are taken together with the nitrogens to which they are attached to form a 6 to 20 member ring.
- 2. The pharmaceutical composition according to claim 1, wherein R1 and R2 are each independently:H, a group selected from (Ci-Cio)alkyl, (C2-C9)heteroalkyl, (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (C6-Ci4)aryl, (C2-C9)heteroaryl, (Ci-Cio)alkylamine, -0(0)C-(Ci-Cio)alkyl, (Ci-Cio)alkyl-COOH, (C3-Cio)cycloalkyl-COOH, -(O)CH3, -OH, amide, a guanidino group represented by Formula (A)NH wherein a is an integer from 0 to 25, a guanidinium chloride group represented by Formula (B),Θ © ClNH2 wherein b is an integer from 0 to 25, a guanidinobenzene group represented by Formula (C), wherein c is an integer from 0 to 25, a dihydroxy group, represented by Formula (D), wherein d is an integer from 0 to 25, or a polyethylene glycol group, represented by Formula (E) wherein e is an integer from 1 to 400.
- 3. The pharmaceutical composition according to claim 1, wherein n is 0.
- 4. The pharmaceutical composition according to claim 1, wherein n is 1.
- 5. The pharmaceutical composition according to claim 1, wherein n is 2.
- 6. The pharmaceutical composition according to claim 1, wherein o is 0.
- 7. The pharmaceutical composition according to claim 1, wherein o is 1.
- 8. The pharmaceutical composition according to claim 1, wherein o is 2.
- 9. The pharmaceutical composition according to claim 1, wherein n is 0 and o is 0.
- 10. The pharmaceutical composition according to claim 1, wherein n is 1 and o is 1.
- 11. The pharmaceutical composition according to claim 1, wherein the compound is a polymer.
- 12. The pharmaceutical composition according to claim 11, wherein the polymer is crosslinked.
- 13. The pharmaceutical composition according to claim 12, wherein the polymer is crosslinked with epichlorohydrin.
- 14. The pharmaceutical composition according to claim 11, wherein the polymer is a copolymer.
- 15. The pharmaceutical composition according to claim 14, wherein the co-polymer is crosslinked.L· l
- 16. The pharmaceutical composition according to claim 15, wherein the co-polymer is crosslinked with epichlorohydrin.
- 17. The pharmaceutical composition according to claim 1, wherein R1 and R2 are each independently H or (Ci-Cio)alkyl.
- 18. The pharmaceutical composition according to claim 16, wherein R1 and R2 are each independently H or -CH3.
- 19. The pharmaceutical composition according to claim 18, wherein Ri and R2 are each H.
- 20. The pharmaceutical composition according to claim 1, wherein R3 and R4 are each independently H or (Ci-Cio)alkyl.
- 21. The pharmaceutical composition according to claim 20, wherein R3 and R4 are each independently H or -CH3.
- 22. The pharmaceutical composition according to claim 21, wherein R3 and R4 are H.
- 23. The pharmaceutical composition according to claim 1, wherein R5 and R6 are each independently H or (Ci-Cio)alkyl.
- 24. The pharmaceutical composition according to claim 23, wherein R5 and R6 are each independently H or -CH3.
- 25. The pharmaceutical composition according to claim 24, wherein R5 and R6 are H.
- 26. The pharmaceutical composition according to claim 1, wherein R5 and R6 are taken together with the nitrogens to which they are attached to form a 6 to 20 member ring.
- 27. The pharmaceutical composition according to claim 26, wherein R5 and R6 are taken together with the nitrogens to which they are attached to form a 14 member ring.
- 28. The pharmaceutical composition according to claim 1, wherein:n is 1;0 is 1;R1 and R2 are each independently a pharmaceutically acceptable end group;R3 and R4 are each H; andR5 and R6 are each H.* λ
- 29. A pharmaceutical composition comprising a compound, wherein the compound comprises the structure of Formula I-A:(I-A) wherein:n is 0, 1, or 2;o is 0, 1, or 2;x is an integer from 2 to 25,000;Y* is each independently a pharmaceutically acceptable anion;R1 and R2 are each independently a pharmaceutically acceptable end group, a polymer, or -Rx-polymer, wherein Rx is selected from (Ci-Cio)alkyl, (C2-C9)heteroalkyl, (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (Cô-Ci4)aryl, (C2-C9)heteroaryl, (Ci-Cio)alkylamine, -0(0)C-(Ci-Cio)alkyl, (Ci-Cio)alkyl-COOH, (C3-Cio)cycloalkyl-COOH, -(O)CH3, -OH, amide;R3 and R4 are each independently H, a polymer, or -Rx-polymer, wherein Rx is selected from (Ci-Cio)alkyl, (C2-C9)heteroalkyl, (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (C6-Ci4)aryl, (C2-C9)heteroaryl, (Ci-Cio)alkylamine, -0(0)C-(Ci-Cio)alkyl, (Ci-Cio)alkyl-COOH, (C3-Cio)cycloalkyl-COOH, -(O)CH3, -OH, amide, or if n is 0 R4 is absent, and if o is 0 R3 is absent; andR5 and R6 are each independently H, (Ci-Cio)alkyl, (C2-C9)heteroalkyl, (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (C6-Ci4)aryl, (C2-C9)heteroaryl, (Ci% iCio)alkylamine, -0(0)C-(Ci-Cio)alkyl, (Ci-Cio)alkyl-COOH, (C3-Cio)cycloalkylCOOH, -(O)CH3, -OH, -NH2, -NH(Ci-Cio)alkyl, -N[(Ci-Cio)alkyl]2 orR5 and R6 are taken together with the nitrogens to which they are attached to form a 6 to 20 member ring.
- 30. The pharmaceutical composition according to claim 29, wherein R1 and R2 are each independently:H, a group selected from (Ci-Cio)alkyl, (C2-C9)heteroalkyl, (C3-Cio)cycloalkyl, (C2-C9)heterocycloalkyl, (C6-Ci4)aryl, (C2-C9)heteroaryl, (Ci-Cio)alkylamine, -O(O)C-(Ci-Cie)alkyl, (Ci-Cio)alkyl-COOH, (C3-Cio)cycloalkyl-COOH, -(O)CH3, -OH, amide, a guanidino group represented by Formula (A)NHH (A) wherein a is an integer from 0 to 25, a guanidinium chloride group represented by Formula (B),Θ © Cl NH2H (B) wherein b is an integer from 0 to 25, a guanidinobenzene group represented by Formula (C),H H J (C) wherein c is an integer from 0 to 25, va dihydroxy group, represented by Formula (D), wherein d is an integer from 0 to 25, or a polyethylene glycol group, represented by Formula (E) kwherein e is an integer from 1 to 400.
- 31. The pharmaceutical composition according to claim 29, wherein Y' is independently carbonate, bicarbonate, or chloride.
- 32. The pharmaceutical composition according to claim 31, wherein Y' is independently carbonate or bicarbonate.
- 33. The pharmaceutical composition according to claim 31, wherein Y’ is chloride.
- 34. The pharmaceutical composition according to claim 29, wherein n is 0.
- 35. The pharmaceutical composition according to claim 29, wherein n is 1.
- 36. The pharmaceutical composition according to claim 29, wherein n is 2.
- 37. The pharmaceutical composition according to claim 29, wherein o is 0.
- 38. The pharmaceutical composition according to claim 29, wherein o is 1.
- 39. The pharmaceutical composition according to claim 29, wherein o is 2.
- 40. The pharmaceutical composition according to claim 29, wherein n is 0 and o is 0.
- 41. The pharmaceutical composition according to claim 29, wherein n is 1 and o is 1.
- 42. The pharmaceutical composition according to claim 29, wherein the compound is a polymer.
- 43. The pharmaceutical composition according to claim 42, wherein the polymer is crosslinked.Ί¢.
- 44. The pharmaceutical composition according to claim 43, wherein the polymer is crosslinked with epichlorohydrin.
- 45. The pharmaceutical composition according to claim 42, wherein the polymer is a copolymer.
- 46. The pharmaceutical composition according to claim 45, wherein the co-polymer is crosslinked.
- 47. The pharmaceutical composition according to claim 46, wherein the co-polymer is crosslinked with epichlorohydrin.
- 48. The pharmaceutical composition according to claim 29, wherein R* and R2 are each independently H or (Ci-Cio)alkyl.
- 49. The pharmaceutical composition according to claim 47, wherein R1 and R2 are each independently H or -CH3.
- 50. The pharmaceutical composition according to claim 49, wherein R1 and R2 are each H.
- 51. The pharmaceutical composition according to claim 29, wherein R3 and R4 are each independently H or (Ci-Cio)alkyl.
- 52. The pharmaceutical composition according to claim 51, wherein R3 and R4 are each independently H or -CH3.
- 53. The pharmaceutical composition according to claim 52, wherein R3 and R4 are H.
- 54. The pharmaceutical composition according to claim 29, wherein R5 and R6 are each independently H or (Ci-Cio)alkyl.
- 55. The pharmaceutical composition according to claim 54, wherein R5 and R6 are each independently H or -CH3.
- 56. The pharmaceutical composition according to claim 55, wherein R5 and R6 are H.
- 57. The pharmaceutical composition according to claim 29, wherein R5 and R6 are taken together with the nitrogens to which they are attached to form a 6 to 20 member ring.
- 58. The pharmaceutical composition according to claim 57, wherein R5 and R6 are taken together with the nitrogens to which they are attached to form a 14 member ring.
- 59. The pharmaceutical composition according to claim 29, wherein:n is 1;i · o is 1;R1 and R2 are each independently a pharmaceutically acceptable end group; andR3 and R4 are each independently H.
- 60. A method of binding AGE precursors in a mammal comprising administering to the mammal a pharmaceutical composition according to claim 1.
- 61. A method of binding dietary dicarbonyls in a mammal comprising administering to the mammal a pharmaceutical composition according to claim 1.10
- 62. A method of binding AGE precursors in a mammal comprising administering to the mammal a pharmaceutical composition according to claim 29.
- 63. A method of binding dietary dicarbonyls in a mammal comprising administering to the mammal a pharmaceutical composition according to claim 29.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61/792719 | 2013-03-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| OA17560A true OA17560A (en) | 2017-02-13 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2771319B1 (en) | Amino acid derivatives functionalized on the n- terminal capable of forming drug incapsulating microspheres | |
| JP6517281B2 (en) | Subcutaneous delivery of polymeric conjugates of therapeutic agents | |
| JP2022037143A (en) | Scavenger of advanced glycation end product (age) precursor | |
| CA2831392A1 (en) | Conjugated lipomers and uses thereof | |
| JP2014529621A (en) | Choline salts of anti-inflammatory substituted cyclobutenedione compounds | |
| TW201043226A (en) | Salts of 3-pentylphenylacetic acid and pharmaceutical uses thereof | |
| US20100093973A1 (en) | Poly(amino acid) compound having inhibitory activity on absorption of phosphorus and phosphorus absorption inhibitor | |
| JP2023529011A (en) | Indene compounds, pharmaceutical compositions thereof, and their therapeutic applications | |
| OA17560A (en) | Sequestrants of advanced glycation end product (AGE) precursors. | |
| AU2015287661B2 (en) | Main chain polyamines | |
| TWI762770B (en) | Water soluble salts of lipidated peptides and methods for preparing and using the same | |
| TW201720465A (en) | Polymeric derivative of macrolide immunosuppressant | |
| US10946028B2 (en) | Polymer conjugate of sulfoxide derivative-coordinated platinum(II) complex | |
| US10945997B2 (en) | Polymer derivative of macrolide immunosuppressant | |
| WO2022213195A1 (en) | Novel modulators of the melatonin receptors as well as method of manufacture and uses thereof | |
| JP6429399B2 (en) | Maleate of anti-prion compound, method for producing the same, and pharmaceutical composition thereof | |
| JP6654057B2 (en) | Composition for controlling local pain comprising a polyion complex containing a local anesthetic as an active ingredient | |
| WO2012121862A2 (en) | Valproic acid derivative compounds |